SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the
Securities Exchange Act of 1934 (Amendment
No. )
Filed by the Registrant x
Filed by a Party other than the Registrant ¨
Check the appropriate box:
| ¨ | Preliminary Proxy Statement |
| ¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| x | Definitive Proxy Statement |
| ¨ | Definitive Additional Materials |
| ¨ | Soliciting Material under §240.14a-12 |
NAVIDEA
BIOPHARMACEUTICALS, INC.
(Name of Registrant as Specified In Its
Charter)
(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| ¨ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11 |
| (1) | Title of each class of securities to which transaction applies: |
| (2) | Aggregate number of securities to which transaction applies: |
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount
on which the filing fee is calculated and state how it was determined): |
| (4) | Proposed maximum aggregate value of transaction: |
| ¨ | Fee paid previously with preliminary materials. |
| ¨ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and
the date of its filing. |
| (1) | Amount Previously Paid: |
| (2) | Form, Schedule or Registration Statement No.: |
2015 ANNUAL MEETING OF STOCKHOLDERS
June 5, 2015
Dear Stockholder:
You are cordially invited to attend the
2015 Annual Meeting of Stockholders of Navidea Biopharmaceuticals, Inc., which will be held at 9:00 a.m., Eastern Daylight Time,
on July 16, 2015, at The Conference Center at OCLC, 6600 Kilgour Place, Dublin, Ohio 43017. The matters on the meeting agenda are
described in the Notice of 2015 Annual Meeting of Stockholders and proxy statement which accompany this letter.
We hope you will be able to attend the meeting,
but regardless of your plans, we ask that you please complete, sign, and date the enclosed proxy card and return it in the envelope
provided, or take advantage of the opportunity to vote online or by telephone, so that your shares will be represented at the meeting.
|
Very truly yours, |
|
|
|
/s/ Ricardo J. Gonzalez |
|
|
|
Ricardo J. Gonzalez |
|
President and Chief Executive Officer |
NAVIDEA
BIOPHARMACEUTICALS, INC.
5600 Blazer Parkway, Suite 200
Dublin, Ohio 43017
NOTICE OF 2015 ANNUAL MEETING OF STOCKHOLDERS
To the Stockholders of
NAVIDEA BIOPHARMACEUTICALS, INC.:
The Annual Meeting of the Stockholders of
Navidea Biopharmaceuticals, Inc., a Delaware corporation (the Company), will be held at The Conference Center at OCLC, 6600 Kilgour
Place, Dublin, Ohio 43017, on July 16, 2015, at 9:00 a.m., Eastern Daylight Time, for the following purposes:
| 1. | To elect two directors, to serve for a term of three years and until their successors are duly elected and qualified; |
| 2. | To ratify the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for 2015; and |
| 3. | To transact such other business as may properly come before the meeting or any adjournment thereof. |
The Board of Directors has fixed the close
of business on May 22, 2015, as the record date for the determination of stockholders entitled to notice of and to vote at the
Annual Meeting and any adjournment thereof. A list of stockholders will be available for examination by any stockholder at the
Annual Meeting and for a period of 10 days before the Annual Meeting at the executive offices of the Company.
Important Notice Regarding the Availability
of Proxy Materials for the Stockholder Meeting to be Held on July 16, 2015: The proxy statement and annual report to security holders
are available at www.proxyvote.com.
Whether or not you plan to attend the
Annual Meeting, please complete, sign, and date the enclosed proxy card and return it in the envelope provided, or take advantage
of the opportunity to vote your proxy online or by telephone.
|
By Order of the Board of Directors |
|
|
|
/s/ Ricardo J. Gonzalez |
|
|
|
Ricardo J. Gonzalez |
|
President and Chief Executive Officer |
Dublin, Ohio
June 5, 2015
NAVIDEA BIOPHARMACEUTICALS, INC.
2015 ANNUAL MEETING OF STOCKHOLDERS
July 16, 2015
PROXY STATEMENT
Dated June 5, 2015
GENERAL INFORMATION
Date, Time and Place of Annual Meeting.
The Annual Meeting of the Stockholders of Navidea Biopharmaceuticals, Inc. will be held at The Conference Center at OCLC, 6600
Kilgour Place, Dublin, Ohio 43017, on July 16, 2015, at 9:00 a.m., Eastern Daylight Time.
Solicitation. This proxy statement
is furnished to the stockholders of Navidea Biopharmaceuticals, Inc., a Delaware corporation, in connection with the solicitation
by the Board of Directors of the Company of proxies to be voted at the Company’s 2015 Annual Meeting of Stockholders to be
held on July 16, 2015, and any adjournment thereof. We have elected to furnish proxy materials and our fiscal 2014 annual report
to many of our stockholders over the Internet pursuant to the rules of the U.S. Securities and Exchange Commission. On or about
June 5, 2015, we mailed to most of our stockholders a Notice of Internet Availability of Proxy Materials (the “Notice”)
containing instructions on how to gain access to our proxy statement and annual report and how to vote online. All other stockholders
received a copy of the proxy statement and annual report by mail on or about June 5, 2015. The Notice also contains instructions
on how you can elect to receive a printed copy of the proxy statement and annual report, if you only received a Notice by mail.
All expenses in connection with this solicitation of proxies will be paid by us. Proxies will be solicited principally by mail,
but directors, officers and certain other individuals authorized by us may personally solicit proxies. We will reimburse custodians,
nominees or other persons for their out-of-pocket expenses in sending proxy materials to beneficial owners.
Company Address. The mailing address
of our principal executive offices is 5600 Blazer Parkway, Suite 200, Dublin, Ohio 43017.
Voting Rights. Stockholders of record
at the close of business on May 22, 2015 (the Record Date), are entitled to notice of and to vote at the Annual Meeting. As of
that date, there were 150,730,438 shares of common stock, par value $0.001 per share (Common Stock) outstanding. Each holder of
Common Stock of record on May 22, 2015, is entitled to one vote per share held with respect to all matters which may be brought
before the Annual Meeting.
Authorization. The shares represented
by the accompanying proxy will be voted as directed if the proxy is properly completed, signed, and received by us or otherwise
properly voted on the Internet or by telephone. The proxy will be voted at the discretion of the persons acting under the proxy
to transact such other business as may properly come before the Annual Meeting and any adjournment thereof. If you are a holder
of record and you sign, date, and send in your proxy but do not indicate how you want to vote, your proxy will be voted “For”
each of the proposals to be voted on at the Annual Meeting.
Revocation. Any stockholder returning
the accompanying proxy has the power to revoke it at any time before its exercise by giving notice of revocation to the Company,
by duly executing and delivering to the Company a proxy card bearing a later date, or by voting in person at the Annual Meeting.
Please note, however, if your shares are held of record by a broker, bank, or other nominee and you wish to vote at the Annual
Meeting, you must obtain from the record holder a proxy issued in your name.
Tabulation. Under Section 216 of
the Delaware General Corporation Law (DGCL) and our bylaws, the presence, in person or by proxy, of the holders of a majority of
the outstanding shares of our Common Stock is necessary to constitute a quorum for the transaction of business at the Annual Meeting.
Shares represented by signed proxies that are returned to the Company will be counted toward the quorum even though they are marked
as “Abstain,” “Against” or “Withhold Authority” on one or more, or all matters, or they are
not marked at all. Brokers, banks, or other nominees who hold their customers’ shares in street name, may, under the applicable
rules of the exchanges and other self-regulatory organizations of which such brokers, banks, or other nominees are members, sign
and submit proxies for such shares and may vote such shares on routine matters. The proposal to ratify the appointment of BDO USA,
LLP as the Company’s independent registered public accounting firm is considered a routine matter. Brokers, banks, or other
nominees may not vote on matters considered non-routine without specific instructions from the customer who owns the shares. The
proposal to elect two directors is not considered a routine matter. Proxies signed and submitted by brokers, banks, or other nominees
that have not been voted on certain matters are referred to as broker non-votes. Such proxies count toward the establishment of
a quorum. We encourage you to provide voting instructions to any broker, bank or other nominee that holds your shares by carefully
following the instructions provided in the notice from such entity.
Under Section 216 of the DGCL and our bylaws,
the election of each director nominee requires the favorable vote of a plurality of all votes cast by the holders of our Common
Stock at a meeting at which a quorum is present. Proxies that are marked “Withhold Authority” and broker non-votes
will not be counted toward a nominee’s achievement of a plurality and, thus, will have no effect.
The proposal to ratify BDO USA, LLC as our
independent registered public accounting firm requires the affirmative vote of a majority of the shares of our Common Stock represented
in person or by proxy at the Annual Meeting. Abstentions will be counted as represented and entitled to vote and will therefore
have the effect of a vote “Against” each proposal. Broker non-votes are disregarded and will have no effect.
Effect of Not Casting Your Vote.
If you hold your shares in street name it is critical that you cast your vote if you want it to count. If you hold your shares
in street name and you do not instruct your bank, broker, or other nominee how to vote, no votes will be cast on your behalf for
any of the proposals to be considered at the Annual Meeting; except, your bank, broker, or other nominee will continue to have
discretion to vote any uninstructed shares on the proposal to ratify the appointment of BDO USA, LLP as the Company’s independent
registered public accounting firm.
PROPOSAL NO. 1 – ELECTION OF DIRECTORS
Nominees for Election as Directors
We presently have seven directors on our
Board of Directors, comprised of three classes with terms expiring at the Annual Meetings in 2015, 2016 and 2017, respectively,
and each containing, three, three and two directors, respectively. At the 2015 Annual Meeting, the nominees to the Board of Directors
receiving the highest number of votes will be elected as directors to a term of three years expiring in 2018.
Our Board of Directors has nominated Peter
F. Drake, Ph.D. and Gordon A. Troup for election as directors to serve for a term of three years. Stockholders may not vote for
a greater number of persons than the number of nominees named. Perry A. Karsen, currently a director of the Company whose term
expires at the Annual Meeting, has notified the Company that he will not stand for re-election at the Annual Meeting, and accordingly
is not included in the nominees, thereby creating a vacancy following the Annual Meeting in the class of directors with terms expiring
in 2018.
Only “For” or “Withhold
Authority” votes are counted in determining whether a plurality has been cast in favor of a director nominee. You cannot
abstain in the election of a director, and broker non-votes are not counted. We have no reason to believe that any nominee will
not stand for election or serve as a director. In the event that a nominee fails to stand for election, the proxies will be voted
for the election of another person designated by the persons named in the proxy. See the section entitled “General Information–Tabulation."
Set forth below is current biographical
information about our directors, including the qualifications, experience and skills that make them suitable for service as a director.
Each listed director’s respective experience and qualifications described below led the Compensation, Nominating and Governance
Committee (CNG Committee) of our Board of Directors to conclude that such director is qualified to serve as a member of our Board
of Directors.
The Board of Directors has nominated
the following persons to serve as directors of the Company until the 2018 Annual Meeting:
Peter F. Drake, Ph.D. has served
as a director of Navidea since April 2011. Dr. Drake began his career as a biotechnology analyst at Kidder, Peabody and Co. where
he was a partner and head of the Healthcare Research Group. In 1988, Dr. Drake co-founded Vector Securities International, an investment
banking firm specializing in the life sciences industry, where he was Executive Vice President and Director of Research. In 1993,
Dr. Drake co-founded Vector Fund Management, a life sciences venture fund, and Deerfield Management, a healthcare hedge fund. In
1999, Vector Securities International was purchased by Prudential Securities, where he was a Managing Director and Head of Healthcare
Research. Dr. Drake is a board member of Trustmark Insurance, a mutual insurance company, and Sequoia Sciences, Inc., a private
biotechnology company. Dr. Drake received his undergraduate degree from Bowdoin College, and his Ph.D. in neurobiology and biochemistry
from Bryn Mawr College.
Gordon A. Troup has served as a director
of Navidea since July 2008. Mr. Troup served as President of the Nuclear Pharmacy Services business at Cardinal Health, Inc. (Cardinal
Health), a multinational medical products and services company, from January 2003 until his retirement in December 2007. Mr. Troup
joined Cardinal Health in 1990 and was appointed Group President of Pharmaceutical Distribution and Specialty Distribution Services
in 1999. Prior to joining Cardinal Health, Mr. Troup was employed for 10 years by American Hospital Supply Corporation and for
3 years by Zellerbach Paper, a Mead Company. Mr. Troup is currently a partner and Chairman of the Board of Scioto Properties, LLC,
a provider of group homes to the developmentally disabled nationwide, and Chairman of the Advisory Board of Guild Associates, Inc.,
a chemical engineering and research and development company serving the energy and military community. Mr. Troup is also a member
of several national healthcare trade organizations and is active in a number of not-for-profit organizations. Mr. Troup has a B.S.
degree in Business Management from San Diego State University.
The Board of Directors unanimously recommends
a vote “FOR” each of the director nominees named above.
Director whose term ends at the 2015 Annual Meeting:
Perry A. Karsen has served as a director
of Navidea since February 2014. Mr. Karsen is currently Chief Executive Officer of Celgene Cellular Therapeutics (CCT), Celgene
Corporation’s placental stem cell research and development division. Previously, he was Executive Vice President and Chief
Operations Officer at Celgene. Mr. Karsen served as President and Chief Executive Officer at Pearl Therapeutics, a privately-held
biotechnology company that was subsequently acquired by Astra-Zeneca, from February 2009 until July 2010. From 2004 to 2009, Mr.
Karsen was Senior Vice President and Head of Worldwide Business Development at Celgene and was also responsible for emerging businesses
as President, Asia/Pacific Region. Mr. Karsen also held executive roles at Human Genome Sciences, Bristol-Myers Squibb, Genentech
and Abbott Laboratories. In addition, Mr. Karsen was a General Partner at Pequot Ventures. Mr. Karsen is a member of the Board
of Directors of the Biotechnology Industry Organization (BIO) and a member of the Executive Committee; he is a member of the Board
of Directors for the Life Sciences Foundation; a member of the Board of Directors of Agios Pharmaceuticals; and a member of the
Board of Directors of Aquilla, Inc. Mr. Karsen has a Masters of Management degree from Northwestern University’s Kellogg
Graduate School of Management, a Masters in Teaching of Biology from Duke University, and a B.S. in Biological Sciences from the
University of Illinois, Urbana.
Directors whose terms end at the 2016 Annual Meeting:
Brendan A. Ford has served as a director
of Navidea since July 2010. Since 2007, Mr. Ford has been a partner in Talisman Capital Partners, a private investment partnership
focusing on middle-market companies. From 1991 through 2007, Mr. Ford served in various executive positions including Executive
Vice President, Business Development and Corporate Strategy with Cardinal Health, Inc., primarily in capacities related to mergers,
acquisitions and related strategic activities, and was involved in over $19 billion in acquisition and disposition transactions
for Cardinal. Prior to his service with Cardinal Health, Mr. Ford practiced law with Baker and Hostetler from 1986 to 1991. From
1980 to 1983, Mr. Ford was employed by Touche Ross LLP as a certified public accountant. Mr. Ford has a B.S. in Business from Miami
University, and a J.D. from The Ohio State University. Mr. Ford serves as a director and board committee member for several privately
held companies.
Eric K. Rowinsky, M.D. has served
as a director of Navidea since July 2010. Dr. Rowinsky has served as the Head of Research and Development and Chief Medical Officer
of Stemline Therapeutics, Inc. since January 2012. From 2005 to 2009, he served as the Chief Medical Officer and Executive Vice
President of Clinical Development, Medical Affairs and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company.
Prior to that, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute of Drug Development,
including Director of the Institute, Director of Clinical Research and SBC Endowed Chair for Early Drug Development, and concurrently
served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at
San Antonio. Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins University School of Medicine and on active
staff at the Johns Hopkins School of Medicine from 1987 to 1996. Dr. Rowinsky is a member of the boards of directors of Biogen
Idec, Inc., BIND Therapeutics, Inc., and Coronado Biosciences, Inc., publicly-held life sciences companies. Dr. Rowinsky has extensive
research and drug development experience, oncology expertise and broad scientific and medical knowledge.
Anton Geuth
joined our Board of Directors in June 2015. Mr. Gueth began his career in the pharmaceutical business over 30 years ago at Eli
Lilly and Company. His global finance and operating experience spans the U.S., Europe, the Middle East and Africa, including Area
Director Africa/Middle East and Vice President of Finance for PCS Health Systems. Before joining EVOLUTION Life Science Partners,
Mr. Gueth was a Managing Director of Burrill Merchant Bank. He is also the founder and Managing Partner of Gueth Consulting LLC,
a consulting firm focusing on pharmaceutical and biotechnology clients in the areas of licensing, early stage financing and alliance
management. Mr. Gueth is a member of the board of directors of Antares Pharma. He is also on the board of the California chapter
of the American Liver Foundation. An author and lecturer, Mr. Gueth has contributed to industry reports from In Vivo and Ernst
and Young as well as business texts on strategic alliances. Mr. Gueth received his master’s degree in public affairs from
Indiana University and an M.S. in agricultural economics from Justus Liebig University in Germany.
Directors whose terms continue until the 2017 Annual Meeting:
Michael M. Goldberg, M.D. has served
as a director of Navidea since November 2013. Dr. Goldberg has served as a Managing Partner of Montaur Capital Partners since January
2007. Dr. Goldberg served as the Chief Executive Officer of Emisphere Technologies, Inc., from August 1990 to January 2007 and
as its President from August 1990 to October 1995. He served as Vice President of The First Boston Corp., where he was a founding
member of the Healthcare Banking Group. Dr. Goldberg is or has been a director of Alliqua, Inc., Echo Therapeutics, Inc., AngioLight,
Inc., Urigen Pharmaceuticals, Inc., and Adventrx Pharmaceuticals, Inc. Dr. Goldberg received a B.S. degree from Rensselaer Polytechnic
Institute, an M.D. from Albany Medical College of Union University in 1982, and an M.B.A. from Columbia University Graduate School
of Business in 1985.
Ricardo J. Gonzalez has served as
President and Chief Executive Officer of Navidea since January 2015, and as Chief Executive Officer from October 2014 to December
2014. Prior to joining Navidea, Mr. Gonzalez held positions of increasing responsibility at Spectrum Pharmaceuticals, Inc. (Spectrum)
from March 2008 to October 2014. While at Spectrum, Mr. Gonzalez led teams in the U.S. and abroad and played an active role in
the evolution of the organization from a product development company to a global commercial enterprise. Most recently he was responsible
for designing and leading the globalization and commercialization strategy for international markets including Europe, Asia, Middle
East and Latin America. Of Mr. Gonzalez’s over 20 years of experience in the pharmaceutical industry, 14 years have been
focused in specialty markets, including HIV/AIDS, Hematology and Oncology. Mr. Gonzalez’s prior experience includes roles
in all aspects of product commercialization including sales, marketing, operations, distribution, managed markets, contracting,
reimbursement, pricing and government affairs with several companies including Abraxis Oncology, Genzyme, Ligand Pharmaceuticals,
Roche Laboratories and GlaxoSmithKline. Mr. Gonzalez earned his B.S. in Business Logistics from Penn State University.
PROPOSAL NO. 2 – RATIFICATION OF
THE INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
BDO USA, LLP (BDO) was engaged as the Company’s
principal accountant on September 27, 2005, and has audited the Company’s financial statements for each of the ten fiscal
years in the period ended December 31, 2014. The Audit Committee has selected BDO as the Company’s independent registered
public accounting firm for purposes of auditing our financial statements for the current fiscal year ending December 31, 2015.
Although not required, the Board of Directors is submitting its selection to the stockholders of the Company for ratification.
The Board of Directors will reconsider the appointment of BDO if its selection is not ratified by the stockholders. A representative
of BDO is expected to be present at the Annual Meeting. The representative will have an opportunity to make a statement if he so
desires and is expected to be available to respond to appropriate questions of stockholders.
The Board of Directors recommends that
our stockholders vote “FOR” ratification of the appointment of BDO.
Information
Concerning the Board of Directors
and
Executive Officers
Directors
Set forth below are the names and committee assignments of the
persons who constitute our Board of Directors.
Name |
|
Age |
|
Committee(s) |
Peter F. Drake, Ph.D. |
|
61 |
|
Compensation, Nominating and Governance (Chairman) |
Brendan A. Ford |
|
57 |
|
Audit (Chairman) |
Michael M. Goldberg, M.D. |
|
56 |
|
— |
Ricardo J. Gonzalez |
|
44 |
|
— |
Anton Gueth |
|
58 |
|
— |
Perry A. Karsen |
|
60 |
|
Audit; Compensation, Nominating and Governance |
Eric K. Rowinsky, M.D. |
|
58 |
|
— |
Gordon A. Troup |
|
61 |
|
Audit; Compensation, Nominating and Governance |
Director Qualifications
The Board of Directors believes that individuals
who serve on the Board should have demonstrated notable or significant achievements in their respective field; should possess the
requisite intelligence, education and experience to make a significant contribution to the Board and bring a range of skills, diverse
perspectives and backgrounds to its deliberations; and should have the highest ethical standards, a strong sense of professionalism
and intense dedication to serving the interests of our stockholders. The following are qualifications, experience and skills for
Board members which are important to our business and its future:
| · | General Management. Directors who have served in senior leadership positions are important to us as they bring experience
and perspective in analyzing, shaping, and overseeing the execution of important operational and policy issues at a senior level.
These directors’ insights and guidance, and their ability to assess and respond to situations encountered in serving on our
Board of Directors, are enhanced by their leadership experience developed at businesses or organizations that operated on a global
scale, faced significant competition, or involved other evolving business models. |
| · | Industry Knowledge. Because we are a pharmaceutical development company, education or experience in our industry, including
medicine, pharmaceutical development, marketing, distribution, or the regulatory environment, is important because such experience
assists our Directors in understanding and advising our Company. |
| · | Business Development/Strategic Planning. Directors who have a background in strategic planning, business development,
strategic alliances, mergers and acquisitions, and teamwork and process improvement provide insight into developing and implementing
strategies for growing our business. |
| · | Finance/Accounting/Control. Knowledge of capital markets, capital structure, financial control, audit, reporting, financial
planning, and forecasting are important qualities of our directors because such qualities assist in understanding, advising, and
overseeing our Company’s capital structure, financing and investing activities, financial reporting, and internal control
of such activities. |
| · | Board Experience/Governance. Directors who have served on other public company boards can offer advice and insights
with regard to the dynamics and operation of a board of directors, the relations of a board to the chief executive officer and
other management personnel, the importance of particular agenda and oversight matters, and oversight of a changing mix of strategic,
operational, and compliance-related matters. |
Board of Directors Meetings
Our Board of Directors held a total of 21
meetings in the fiscal year ended December 31, 2014, and each of the directors attended at least 75 percent of the aggregate number
of meetings of the Board of Directors and committees (if any) on which he served. It is our policy that all directors attend the
Annual Meeting of Stockholders. However, conflicts and unforeseen events may prevent the attendance of a director, or directors.
All then-current members of our Board of Directors attended the 2014 Annual Meeting of Stockholders in person.
Board of Directors Leadership Structure and Role in Risk
Oversight
Our Board of Directors has determined that
it is generally in the best interests of the Company and its stockholders that the roles of Chairman of the Board and Chief Executive
Officer be held by different individuals within our organization. Our Chief Executive Officer is responsible for setting the strategic
direction for the Company and the day-to-day leadership and performance of the Company, while the Chairman of the Board, Gordon
A. Troup, provides strategic guidance, presides over meetings of the full Board of Directors, and acts as the lead independent
director. The Board of Directors believes that this structure helps facilitate the role of the independent directors in the oversight
of the Company and the active participation of the independent directors in setting agendas and establishing priorities and procedures
that work for the Board of Directors. The Chairman of the Board also acts as a key liaison between the Board of Directors and management.
Moreover, in addition to feedback provided during the course of meetings of the Board of Directors, our independent directors have
executive sessions led by the Chairman of the Board. Our Chairman of the Board acts as a liaison between the independent directors
and the Chief Executive Officer regarding any specific feedback or issues following an executive session of independent directors,
provides the Chief Executive Officer with input regarding agenda items for Board of Director and committee meetings, and coordinates
with the Chief Executive Officer regarding information to be provided to the independent directors in performing their duties.
From time to time, particularly during periods of leadership transition, a lead independent director may be appointed until an
independent Chairman of the Board is named.
Our Chief Executive Officer and senior management
are responsible for the day-to-day management of the risks we face. Our Board of Directors, as a whole and through its committees,
has responsibility for the oversight of risk management, including general oversight of (i) the financial exposure of the Company,
(ii) risk exposure as related to overall company portfolio and impact on earnings, (iii), oversight for information technology
security and risk, and (iv) all systems, processes, and organizational structures and people responsible for finance and risk functions.
Certain risks are overseen by committees of the Board of Directors and these committees make reports to the full Board of Directors,
including reports on noteworthy risk management issues. Financial risks are overseen by the Audit Committee which meets with management
to review the Company’s major financial risk exposure and the steps management has taken to monitor and control such exposures.
Compensation risks are overseen by the CNG Committee.
Members of the Company’s senior management
report to the full Board of Directors about their areas of responsibility, including reports regarding risk within such area of
responsibility and the steps management has taken to monitor and control such exposures. Additional review or reporting of risks
is conducted as needed or as requested by the Board of Directors or committee.
Independence
Our Board of Directors has adopted the definition
of “independence” as described under the Sarbanes-Oxley Act of 2002 (Sarbanes-Oxley) Section 301, Rule 10A-3 under
the Securities Exchange Act of 1934 (the Exchange Act) and Section 803A of the NYSE MKT Company Guide. Our Board of Directors has
determined that Messrs. Ford, Gueth, Karsen and Troup, and Dr. Drake, meet the independence requirements.
Compensation, Nominating and Governance Committee
The CNG Committee of the Board of Directors
discharges the Board’s responsibilities relating to the compensation of the Company's directors, executive officers and associates,
identifies and recommends to the Board of Directors nominees for election to the Board, and assists the Board in the implementation
of sound corporate governance principles and practices. With respect to its compensation functions, the CNG Committee evaluates
and approves executive officer compensation and reviews and makes recommendations to the Board with respect to director compensation,
including incentive or equity-based compensation plans; reviews and evaluates any discussion and analysis of executive officer
and director compensation included in the Company’s annual report or proxy statement, and prepares and approves any report
on executive officer and director compensation for inclusion in the Company’s annual report or proxy statement required by
applicable rules and regulations; and monitors and evaluates, at the Committee’s discretion, matters relating to the compensation
and benefits structure of the Company and such other domestic and foreign subsidiaries or affiliates, as it deems appropriate.
The members of our CNG Committee are: Peter F. Drake, Ph.D. (Chairman), Perry A. Karsen, and Gordon A. Troup. The CNG Committee
held two meetings in the fiscal year ended December 31, 2014 to complement compensation-related discussions held by the full Board.
The Board of Directors adopted a written Compensation, Nominating and Governance Committee Charter on February 26, 2009. A copy
of the Compensation, Nominating and Governance Committee Charter is posted on the Company’s website at www.navidea.com.
The Committee strives to provide fair compensation
to executive officers based on their performance and contribution to the Company and to provide incentives that attract and retain
key executives, instill a long-term commitment to the Company, and develop a sense of pride and Company ownership, all in a manner
consistent with stockholder interests. In addition, the Committee strives to provide fair compensation to directors, taking into
consideration compensation paid to directors of comparable companies and the specific duties of each director.
With respect to its nominating and governance
functions, the Committee’s purpose is to:
| · | Assist the Board of Directors by identifying individuals qualified to become Board members, and recommend to the Board of Directors
the director nominees whenever directors are to be appointed or elected, whether at the next annual meeting of stockholders or
otherwise; |
| · | Review the qualifications and independence of the members of the Board of Directors and its various committees on a periodic
basis and make any recommendations to the Board of Directors which the Committee may deem appropriate concerning any recommended
changes in the composition or membership of the Board of Directors, or any of its committees; |
| · | Develop and recommend to the Board of Directors any policies it may deem appropriate with regard to consideration of director
candidates to be recommended to security holders; |
| · | Develop and recommend to the Board of Directors corporate governance principles applicable to the Company; |
| · | Conduct the annual review of the performance of the Board of Directors, the committees of the Board of Directors and Company’s
executive management; |
| · | Recommend to the Board of Directors director nominees for each committee; and |
| · | Develop and recommend to the Board of Directors any policies or processes it may deem appropriate for security holders to send
communications to the Board of Directors. |
Our directors play a critical role in guiding
our strategic direction and oversee the management of our Company. Board candidates are considered based on various criteria, such
as their broad based business and professional skills and experiences, a global business and social perspective, concern for long
term interests of stockholders, and personal integrity and judgment. In addition, directors must have available time to devote
to Board activities and to enhance their knowledge of the industry. Accordingly, we seek to attract and retain highly qualified
directors who have sufficient time to attend to their substantial duties and responsibilities to our Company. Recent developments
in corporate governance and financial reporting have resulted in an increased demand for such highly qualified and productive public
company directors. The Committee does not have a formal policy with regard to the consideration of diversity in identifying director
nominees; however, how a specific nominee contributes to the diversity of the Board of Directors is considered by the Committee
in determining candidates for the Board. The Committee and the Board consider diversity by identifying a nominee’s experience
and background and determining how such experience and background will complement the overall makeup of the Board. The Committee
and the Board prefer nominees who will contribute to a board that is diverse in terms of business training, experience across a
range of industries, leadership, background, and education.
Our Board of Directors will consider the
recommendations of stockholders regarding potential director candidates. In order for stockholder recommendations regarding possible
director candidates to be considered by our Board of Directors:
| · | such recommendations must be provided to the Board of Directors c/o Brent L. Larson, Navidea
Biopharmaceuticals, Inc., 5600 Blazer Parkway, Suite 200, Dublin, Ohio 43017, in writing at least 120 days prior to the one year
anniversary date of the Company’s proxy statement released to stockholders in connection with this year’s annual meeting;
provided, however, that if the date of the current year’s annual meeting is more than 30 days
before or after the first anniversary of the most recently concluded annual meeting, such notice shall be delivered to the Company
not more than seven days after the date of the notice of the annual meeting. |
| · | the nominating stockholder must meet the eligibility requirements to submit a valid stockholder proposal under Rule 14a-8 of
the Securities Exchange Act of 1934, as amended; |
| · | the stockholder must describe the qualifications, attributes, skills or other qualities of the recommended director candidate;
and |
| · | the stockholder must follow the procedures set forth in Article III, Section 2 of our Bylaws. |
Audit Committee
The Audit Committee of the Board of Directors
selects our independent registered public accounting firm with whom the Audit Committee reviews the scope of audit and non-audit
assignments and related fees, the accounting principles that we use in financial reporting, and the adequacy of our internal control
procedures. The members of our Audit Committee are: Brendan A. Ford (Chairman), Perry A. Karsen, and Gordon A. Troup, each of whom
is “independent” under Section 803A of the NYSE MKT Company Guide. The Board of Directors has determined that Brendan
A. Ford meets the requirements of an “audit committee financial expert” as set forth in Section 407(d)(5) of Regulation
S-K promulgated by the SEC. The Audit Committee held five meetings in the fiscal year ended December 31, 2014. The Board of Directors
adopted a written Amended and Restated Audit Committee Charter on April 30, 2004. A copy of the Amended and Restated Audit Committee
Charter is posted on the Company’s website at www.navidea.com.
REPORT OF AUDIT COMMITTEE OF THE BOARD
OF DIRECTORS
The Audit Committee consults with our Chief
Financial Officer and other key members of our management and with our independent registered public accounting firm with regard
to their year-end audit plan, the results of its quarterly reviews conducted in accordance with Public Company Accounting Oversight
Board (PCAOB) Interim Standard AU 722, the auditor’s report of audit, and the accompanying management letter, if any; and
consults with our Chief Financial Officer and other key members of our management and with our independent registered public accounting
firm with regard to the adequacy of our internal accounting controls.
In fulfilling its responsibilities, the
Audit Committee selected BDO USA, LLP (BDO) as our independent registered public accounting firm for purposes of auditing our financial
statements for the fiscal year ended December 31, 2014. The Audit Committee has reviewed and discussed with management and BDO
our audited financial statements; discussed with BDO the matters required to be discussed by PCAOB Auditing Standard No. 16 (Communications
with Audit Committee); received the written disclosures and the letter from BDO required by applicable requirements of the PCAOB
regarding the independent registered public accounting firm’s communications with the Audit Committee concerning independence,
and has discussed with BDO its independence from our Company.
Based on the reviews and discussions with
management and BDO, the Audit Committee recommended to the Board of Directors that our audited consolidated financial statements
be included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, and filed with the Securities and Exchange
Commission.
The Board of Directors evaluated the independence
of each member of the Audit Committee. As part of its evaluation, the Board of Directors determined, in the exercise of its business
judgment, that each of Messrs. Ford, Karsen and Troup is independent under Section 803A of the NYSE MKT Company Guide and is financially
literate.
Based upon its work and the information
received in the inquiries outlined above, the Audit Committee is satisfied that its responsibilities under the charter for the
period ended December 31, 2014, were met and that our financial reporting and audit processes are functioning effectively.
|
Submitted by the Audit Committee |
|
of the Board of Directors: |
|
|
|
Brendan A. Ford, Chairman |
|
Perry A. Karsen |
|
Gordon A. Troup |
Stockholder Communications
Stockholders may send communications to
our Board of Directors, or to individual directors, by mailing communications in writing to Navidea Biopharmaceuticals, Inc., c/o
Brent L. Larson, 5600 Blazer Parkway, Suite 200, Dublin, OH 43017.
Executive Officers
In addition to Mr. Gonzalez, the following
individuals are executive officers of Navidea and serve in the position(s) indicated below:
Name |
|
Age |
|
Position |
Frederick O. Cope, Ph.D. |
|
68 |
|
Senior Vice President and Chief Scientific Officer |
Thomas J. Klima |
|
43 |
|
Senior Vice President and Chief Commercial Officer |
Brent L. Larson |
|
52 |
|
Executive Vice President, Chief Financial Officer, Treasurer and Secretary |
William J. Regan |
|
63 |
|
Senior Vice President, Global Regulatory Affairs and
Quality and Chief Compliance Officer |
Frederick O. Cope, Ph.D., F.A.C.N., C.N.S.,
has served as Chief Scientific Officer of Navidea since May of 2013, Senior Vice President, Pharmaceutical Research and Clinical
Development of Navidea since July 2010 and as Vice President, Pharmaceutical Research and Clinical Development from February 2009
to July 2010. Prior to accepting his position with Navidea, Dr. Cope served as the Assistant Director for Research and Head of
Program Research Development for The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital and The Richard
J. Solove Research Institute, from April 2001 to February 2009. Dr. Cope also served as head of the Cancer and AIDS product development
and commercialization program for the ROSS/Abbott Laboratories division for 10 years, and head of human and veterinary vaccine
production and improvement group for Wyeth Laboratories for seven years. Dr. Cope served a fellowship in oncology at the McArdle
Laboratory for Cancer Research at the University of Wisconsin and was the honored scientist in residence at the National Cancer
Center Research Institute in Tokyo; he is the recipient of the Ernst W. Volwiler Research Award. Dr. Cope is also active in a number
of professional and scientific organizations such as serving as an editorial reviewer for several professional journals, and as
an advisor/director to the research program of Roswell Park Memorial Cancer Center. Dr. Cope received his B.Sc. from the Delaware
Valley College of Science and Agriculture, his M.S. from Millersville University of Pennsylvania and his Ph.D. from the University
of Connecticut with full honors.
Thomas J. Klima has served as Senior
Vice President and Chief Commercial Officer of Navidea since January 2015. Before joining Navidea, Mr. Klima served as National
Sales Director/Head of Sales of Algeta from September 2012 to April 2014, when Algeta was acquired by Bayer AG. Mr. Klima led oncology
strategy for Bayer from April 2014 to December 2014. Prior to that, Mr. Klima was Senior Director, Marketing at Dendreon Corporation
from September 2009 to September 2012. From February 2000 to September 2009, Mr. Klima held positions of increasing responsibility
at Eli Lilly, most recently serving as Director, Marking US Cymbalta Brand Team. Mr. Klima has a B.A. degree in Business Administration
and Marketing from Western State College.
Brent L. Larson has served as Executive
Vice President of Navidea since May 2013, as Senior Vice President from July 2010 to April 2013, as Vice President, Finance from
July 1998 to June 2010, and as Controller from July 1996 to June 1998. Mr. Larson has also served as Navidea’s Chief Financial
Officer and Treasurer since February 1999 and as Secretary since 2003. Before joining Navidea, Mr. Larson was employed by Price
Waterhouse LLP. Mr. Larson has a B.B.A. degree in accounting from Iowa State University of Science and Technology and is a Certified
Public Accountant.
William J. Regan has served as Chief
Compliance Officer of Navidea since March 2015, as Senior Vice President, Global Regulatory Affairs and Quality since February
2014, and as Senior Vice President, Global Regulatory Strategy of Navidea from October 2012 to January 2014. Prior to accepting
his position with Navidea, Mr. Regan served as a consultant to Navidea from July 2011 to September 2012. As Principal of Regan
Advisory Services (RAS) from September 2006 to September 2012, Mr. Regan consulted on all aspects of regulatory affairs within
pharmaceutical, biotechnology and diagnostic imaging businesses, including PET diagnostic agents (cardiovascular, neurology, and
oncology), contrast agents, and radiopharmaceuticals. Previous to RAS, Mr. Regan held roles of increasing responsibility in radiopharmaceutical
manufacturing, quality assurance, pharmaceutical technology and regulatory affairs at Bristol-Myers Squibb (BMS). From September
2001 to August 2006, he served as global regulatory head for BMS’ Medical Imaging business where he was responsible for all
regulatory aspects of the company’s in-market and pipeline products and led regulatory actions resulting in product approvals.
Mr. Regan has been an active member in the Society of Nuclear Medicine, Council on Radionuclides and Radiopharmaceuticals (CORAR),
and Medical Imaging and Technology Alliance, and formerly served as the industry chair of the Regulatory and Clinical Practice
committee on behalf of CORAR. Mr. Regan holds a B.A. in Chemistry from Rutgers University.
SECURITIES OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT
The following table sets forth, as of May
22, 2015, certain information with respect to the beneficial ownership of shares of our common stock by: (i) each person known
to us to be the beneficial owner of more than 5% of our outstanding shares of common stock, (ii) each director or nominee
for director of our Company, (iii) each of the Named Executive Officers (see “Executive Compensation – Summary
Compensation Table”), and (iv) our directors and executive officers as a group.
Beneficial Owner | |
Number of Shares Beneficially Owned (*) | | |
Percent of Class (**) | |
Frederick O. Cope, Ph.D. | |
| 535,189 | (a) | |
| — | (l) |
Peter F. Drake, Ph.D. | |
| 77,829 | (b) | |
| — | (l) |
Brendan A. Ford | |
| 208,633 | (b) | |
| — | (l) |
Michael M. Goldberg, M.D. | |
| 296,325 | (c) | |
| — | (l) |
Ricardo J. Gonzalez | |
| — | (d) | |
| | (l) |
Perry A. Karsen | |
| 37,528 | (c) | |
| — | (l) |
Brent L. Larson | |
| 910,818 | (e) | |
| — | (l) |
Cornelia B. Reininger, M.D., Ph.D. | |
| 144,392 | (f) | |
| — | (l) |
Eric K. Rowinsky, M.D. | |
| 237,484 | (g) | |
| — | (l) |
Gordon A. Troup | |
| 209,755 | (h) | |
| — | (l) |
Thomas H. Tulip, Ph.D. | |
| 407,216 | (i) | |
| — | (l) |
All directors and executive officers as a group (13 persons) | |
| 3,260,522 | (j)(m) | |
| 2.1 | % |
Platinum-Montaur Life Sciences, LLC | |
| 11,454,831 | (k) | |
| 7.6 | % |
| (*) | Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission which generally attribute
beneficial ownership of securities to persons who possess sole or shared voting power and/or investment power with respect to those
securities. Unless otherwise indicated, voting and investment power are exercised solely by the person named above or shared with
members of such person’s household. |
| (**) | Percent of class is calculated on the basis of the number of shares outstanding on May 22, 2015, plus the number of shares
the person has the right to acquire within 60 days of May 22, 2015. |
| (a) | This amount includes 446,000 shares issuable upon exercise of options which are exercisable within 60 days and 13,375 shares
in Dr. Cope’s account in the 401(k) Plan, but it does not include 50,000 shares of unvested restricted stock and 366,000
shares issuable upon exercise of options which are not exercisable within 60 days. |
| (b) | This amount does not include 39,000 shares of unvested restricted stock. |
| (c) | This amount does not include 22,000 shares of unvested restricted stock. |
| (d) | This amount does not include 1,000,000 shares issuable upon exercise of options which are not exercisable within 60 days. |
| (e) | This amount includes 503,000 shares issuable upon exercise of options which are exercisable within 60 days and 98,081 shares
in Mr. Larson’s account in the 401(k) Plan, but it does not include 337,000 shares issuable upon exercise of options which
are not exercisable within 60 days. |
| (f) | This amount includes 139,750 shares issuable upon exercise of options which are exercisable within 60 days and 4,642 shares
in Dr. Reininger’s account in the 401(k) Plan, but does not include 211,250 shares issuable upon exercise of options which
are not exercisable within 60 days. |
| (g) | This amount includes 73,764 shares issuable upon exercise of options which are exercisable within 60 days, but it does not
include 39,000 shares of unvested restricted stock. |
| (h) | This amount includes 20,000 shares issuable upon exercise of options which are exercisable within 60 days, but it does not
include 39,000 shares of unvested restricted stock. |
| (i) | This amount includes 329,250 shares issuable upon exercise of options which are exercisable within 60 days and 7,193 shares
in Dr. Tulip's account in the 401(k) Plan, but it does not include 20,000 shares of unvested restricted stock and 267,750 shares
issuable upon exercise of options which are not exercisable within 60 days. |
| (j) | This amount includes 1,672,264 shares issuable upon exercise of options which are exercisable within 60 days and 128,144 shares
held in the 401(k) Plan on behalf of certain officers, but it does not include 370,000 shares of unvested restricted stock and
2,600,500 shares issuable upon the exercise of options which are not exercisable within 60 days. The Company itself is the trustee
of the Navidea Biopharmaceuticals, Inc. 401(k) Plan and may, as such, share investment power over common stock held in such plan.
The trustee disclaims any beneficial ownership of shares held by the 401(k) Plan. The 401(k) Plan holds an aggregate total of 376,963
shares of common stock. The 13 persons referenced in this disclosure include each director and named executive officer listed in
the table as well as two additional executive officers who are not named executive officers. |
| (k) | Based on information filed on Schedule 13F with the Securities and Exchange Commission on May 15, 2015. The number of shares
beneficially owned by Platinum-Montaur Life Sciences, LLC (Platinum), 250 West 55th Street, 14th Floor, New York, NY 10019, does
not include 14,777,130 shares of common stock issuable upon conversion of 4,519 shares of Series B Convertible Preferred Stock.
The Certificate of Designation of the Preferred Stock provides that the holder of shares of the Preferred Stock may not convert
any of the Preferred Stock to the extent that such conversion or exercise would result in the holder and its affiliates together
beneficially owning more than 9.99% of the outstanding shares of common stock, except on 61 days’ prior written notice to
Navidea that the holder waives such limitation. |
| (l) | Less than one percent. |
| (m) | The address of all directors and executive officers is c/o Navidea Biopharmaceuticals, Inc., 5600 Blazer Parkway, Suite 200,
Dublin, OH 43017. |
EXECUTIVE COMPENSATION
Compensation Discussion and Analysis
Overview of Compensation Program.
The CNG Committee of the Board of Directors is responsible for establishing and implementing our compensation policies applicable
to senior executives and monitoring our compensation practices. The CNG Committee seeks to ensure that our compensation plans are
fair, reasonable and competitive. The CNG Committee is responsible for reviewing and approving all senior executive compensation,
all awards under our cash bonus plan, and awards under our equity-based compensation plans.
Philosophy and Goals of Executive Compensation
Plans. The CNG Committee’s philosophy for executive compensation is to:
| · | Pay for performance — The CNG Committee believes that our executives should be compensated based upon their ability to
achieve specific operational and strategic results. Therefore, our compensation plans are designed to provide rewards for the individual’s
contribution to our performance. |
| · | Pay commensurate with other companies categorized as value creators — The CNG Committee has set a goal that the Company
should move towards compensation levels for senior executives that are at or above the 40th to 50th percentile for similar executives
in the workforce while taking into account current market conditions and Company performance. This allows us to attract, hire,
reward and retain senior executives who formulate and execute our strategic plans and drive exceptional results. |
To ensure our programs are competitive,
the CNG Committee reviews compensation information of peer companies, national data and trends in executive compensation to help
determine the appropriateness of our plans and compensation levels. These reviews, and the CNG Committee’s commitment to
pay for performance, become the basis for the CNG Committee’s decisions on compensation plans and individual executive compensation
payments.
The CNG Committee has approved a variety
of programs that work together to provide a combination of basic compensation and strong incentives. While it is important for
us to provide certain base level salaries and benefits to remain competitive, the CNG Committee’s objective is to provide
compensation plans with incentive opportunities that motivate and reward executives for consistently achieving superior results.
The CNG Committee designs our compensation plans to:
| · | Reward executives based upon overall company performance, their individual contributions and creation of stockholder value; |
| · | Encourage top performers to make a long-term commitment to our Company; and |
| · | Align executive incentive plans with the long-term interests of stockholders. |
The CNG Committee reviews competitive information
and individual compensation levels at least annually. During the review process, the CNG Committee addresses the following questions:
| · | Do any existing compensation plans need to be adjusted to reflect changes in competitive practices, different market circumstances
or changes to our strategic initiatives? |
| · | Should any existing compensation plans be eliminated or new plans be added to the executive compensation programs? |
| · | What are the compensation-related objectives for our compensation plans for the upcoming fiscal year? |
| · | Based upon individual performance, what compensation modifications should be made to provide incentives for senior executives
to perform at superior levels? |
In addressing these questions, the CNG Committee
considers input from management, outside compensation experts and published surveys of compensation levels and practices.
The CNG Committee does not believe that
our compensation policies and practices for our employees give rise to risks that are reasonably likely to have a material adverse
effect on the Company. As noted below, our incentive-based compensation is generally tied to Company financial performance (i.e.,
revenue or gross margin) or product development goals (i.e., clinical trial progress or regulatory milestones). The CNG Committee
believes that the existence of these financial performance incentives creates a strong motivation for Company employees to contribute
towards the achievement of strong, sustainable financial and development performance, and believes that the Company has a strong
set of internal controls that minimize the risk that financial performance can be misstated in order to achieve incentive compensation
payouts.
In addition to the aforementioned considerations,
the CNG Committee also takes into account the outcome of stockholder advisory (“say-on-pay”) votes, taken every three
years, on the compensation of our Chief Executive Officer, Chief Financial Officer, and our other three highest-paid executive
officers (the Named Executive Officers). At the Annual Meeting of Stockholders held on July 17, 2014, holders of approximately
74% of our common stock represented in person or by proxy at the meeting voted in favor of the resolution relating to the compensation
of our Named Executive Officers. The CNG Committee believes this affirmed stockholders’ support of the Company’s executive
compensation program. The CNG Committee will continue to consider the results of future say-on-pay votes when making future compensation
decisions for the executive officers.
Scope of Authority of the CNG Committee.
The Board of Directors has authorized the CNG Committee to establish the compensation programs for all executive officers and to
provide oversight for compliance with our compensation philosophy. The CNG Committee delegates the day-to-day administration of
the compensation plans to management (except with respect to our executive officers), but retains responsibility for ensuring that
the plan administration is consistent with the Company’s policies. Annually, the CNG Committee sets the compensation for
our executive officers, including objectives and awards under incentive plans. Mr. Gonzalez provides input for the CNG Committee
regarding the performance and appropriate compensation of the other officers. The CNG Committee gives considerable weight to Mr.
Gonzalez’ evaluation of the other officers because of his direct knowledge of each officer’s performance and contributions.
The CNG Committee also makes recommendations to the Board of Directors on appropriate compensation for the non-employee directors.
In addition to overseeing the compensation of executive officers, the CNG Committee approves awards under short-term cash incentive
and long-term equity-based compensation plans for all other employees. For more information on the CNG Committee’s role,
see the CNG Committee’s charter, which can be found on our website at www.navidea.com.
Independent Compensation Expertise.
The CNG Committee is authorized to retain independent experts to assist in evaluating executive compensation plans and in setting
executive compensation levels. These experts provide information on trends and best practices so the CNG Committee can formulate
ongoing plans for executive compensation. The CNG Committee retained Pearl Meyer & Partners (Pearl Meyer) as its independent
expert to assist in the determination of the reasonableness and competitiveness of the executive compensation plans and senior
executives’ individual compensation levels for fiscal 2013. No conflict of interest exists that would prevent Pearl Meyer
from serving as independent consultant to the CNG Committee.
For fiscal 2013, Pearl Meyer performed a
benchmark compensation review of our key executive positions, including our Named Executive Officers. Pearl Meyer utilized both
proprietary survey and proxy reported data from compensation peers, with market data aged to January 1, 2014 by an annualized rate
of 3.0%, the expected pay increase in 2013 for executives in the life sciences industry.
In evaluating appropriate executive compensation,
it is common practice to set targets at a point within the competitive marketplace. The CNG Committee sets its competitive compensation
levels based upon its compensation philosophy. Following completion of the Pearl Meyer study for 2013, the CNG Committee noted
that our overall executive compensation was, on average, between the 25th and 50th percentile for an established peer group of
companies.
Peer Group Companies. In addition
to the above survey analysis, in 2013 the CNG Committee also reviewed the compensation levels at specific competitive benchmark
companies. With input from management, the CNG Committee chose the peer companies because they operate within the biotechnology
industry, have market capitalization between $100 million and $500 million, have similar business models to our Company or have
comparable key executive positions. While the specific plans for these companies may or may not be used, it is helpful to review
their compensation data to provide benchmarks for the overall compensation levels that will be used to attract, hire, retain and
motivate our executives.
As competitors and similarly situated companies
that compete for the same executive talent, the CNG Committee determined that the following peer group companies most closely matched
the responsibilities and requirements of our executives:
OncoGenex Pharmaceuticals, Inc. |
Targacept, Inc. |
ArQule, Inc. |
EXACT Sciences Corp. |
Progenics Pharmaceuticals, Inc. |
Cell Therapeutics, Inc. |
Threshold Pharmaceuticals, Inc. |
Rigel Pharmaceuticals, Inc. |
Curis, Inc. |
ZIOPHARM Oncology, Inc. |
Hyperion Therapeutics, Inc. |
Delcath Systems, Inc. |
Keryx Biopharmaceuticals, Inc. |
TG Therapeutics, Inc. |
Immunomedics, Inc. |
GTx, Inc. |
The CNG Committee used the publicly available
compensation information for these companies to analyze our competitive position in the industry. The CNG Committee reviewed the
base salaries and short-term and long term incentive plans of the executives of these companies to provide background and perspective
in analyzing the compensation levels for our executives.
Specific Elements of Executive Compensation.
Base Salary. Using information gathered
by Pearl Meyer, peer company data, national surveys, general compensation trend information and recommendations from management,
the CNG Committee approved the fiscal 2014 base salaries for our senior executives. Base salaries for senior executives are set
using the CNG Committee’s philosophy that compensation should be competitive and based upon performance. Executives should
expect that their base salaries, coupled with a cash bonus award, would provide them the opportunity to be compensated at or above
the competitive market at the 40th to 50th percentile.
Based on competitive reviews of similar
positions, industry salary trends, overall company results and individual performance, salary increases may be approved from time
to time. The CNG Committee reviews and approves base salaries of all executive officers.
In setting specific base salaries for fiscal
2014, the CNG Committee considered published proxy data for similar positions at peer group companies.
The following table shows the increases
in base salaries for the Named Executive Officers that were approved for fiscal 2014 compared to the approved salaries for fiscal
2013:
Named Executive Officer | |
Fiscal 2014 Base Salary (a) | | |
Fiscal 2013 Base Salary | | |
Change (b) | |
Mark J. Pykett, V.M.D., Ph.D. (c) | |
$ | 399,000 | | |
$ | 437,750 | | |
| (8.9 | )% |
Ricardo J. Gonzalez (d) | |
| 375,000 | | |
| — | | |
| N/A | |
Frederick O. Cope, Ph.D. | |
| 279,130 | | |
| 279,130 | | |
| — | % |
Brent L. Larson | |
| 260,000 | | |
| 279,575 | | |
| (7.0 | )% |
Cornelia B. Reininger, M.D., Ph.D. | |
| 300,000 | | |
| 300,000 | | |
| — | % |
Thomas H. Tulip, Ph.D. | |
| 314,000 | | |
| 339,625 | | |
| (7.5 | )% |
| (a) | The amount shown for fiscal 2014 is the approved annual salary of the Named Executive Officer in effect at the end of 2014.
The actual amount paid to the Named Executive Officer during fiscal 2014 is shown under “Salary” in the Summary Compensation
table below. |
| (b) | Based on the performance of the Company's stock during 2013, Drs. Pykett and Tulip and Mr. Larson agreed to salary reductions
effective January 1, 2014, and Drs. Cope and Reininger did not receive salary increases in 2014. |
| (c) | Dr. Pykett separated from the Company effective May 30, 2014. |
| (d) | Mr. Gonzalez commenced employment with the Company effective October 13, 2014. |
The CNG Committee did not approve any base
salary increases for executive officers in 2015, and base salaries remain at the 2014 levels.
Short-Term Incentive Compensation.
Our executive officers, along with all of our employees, are eligible to participate in our annual cash bonus program, which has
four primary objectives:
| · | Attract, retain and motivate top-quality executives who can add significant value to the Company; |
| · | Create an incentive compensation opportunity that is an integral part of the employee’s total compensation program; |
| · | Reward participants’ contributions to the achievement of our business results; and |
| · | Provide an incentive for individuals to achieve corporate objectives that are tied to our strategic goals. |
The cash bonus compensation plan provides
each participant with an opportunity to receive an annual cash bonus based on our Company’s performance during the fiscal
year. Cash bonus targets for senior executives are determined as a percentage of base salary, based in part on published proxy
data for similar positions at peer group companies. The following are the key provisions of the cash bonus compensation plan:
| · | The plan is administered by the CNG Committee, which has the power and authority to establish, adjust, pay or decline to pay
the cash bonus for each participant, including the power and authority to increase or decrease the cash bonus otherwise payable
to a participant. However, the Committee does not have the power to increase, or make adjustments that would have the effect of
increasing, the cash bonus otherwise payable to any executive officer. The Committee has the right to delegate to the Chief Executive
Officer its authority and responsibilities with respect to the cash bonuses payable to employees other than executive officers. |
| · | All Company employees are eligible to participate. |
| · | The CNG Committee is responsible for specifying the terms and conditions for earning cash bonuses, including establishing specific
performance objectives. Cash bonuses payable to executive officers are intended to constitute “qualified performance-based
compensation” for purposes of Section 162(m) of the Internal Revenue Code. Consequently, each cash bonus awarded to an executive
officer must be conditioned on one or more specified “Performance Measures,” calculated on a consolidated basis. Possible
Performance Measures include revenues; gross margin; operating income; net income; clinical trial progress; regulatory milestones;
or any other performance objective approved by the CNG Committee. |
| · | As soon as reasonably practicable after the end of each fiscal year, the CNG Committee determines whether and to what extent
each specified business performance objective has been achieved and the amount of the cash bonus to be paid to each participant. |
In January 2014, the CNG Committee established
the fiscal 2014 targets and performance measures for all Company employees. For fiscal 2014, the cash bonus for each executive
officer was a function of the designated target bonus amount and certain business performance objectives, weighted as a percentage
of the total target amount. The business performance objectives established for fiscal 2014 were as follows:
| · | Achievement of various development and commercial goals for the Company’s Lymphoseek product, including: |
| o | generation of specified revenue amounts derived directly from Lymphoseek during fiscal 2014, subject to a maximum 40% reduction
of bonus if not achieved; |
| o | approval of the sNDA for Lymphoseek for head and neck cancer, subject to a maximum 5% reduction of bonus if not achieved; and |
| o | initiation of ex-U.S. commercial launch activities in select countries, subject to a maximum 5% reduction of bonus if not achieved. |
| · | Achievement of a specified percentage of the total target enrollment in the Company’s NAV4-02 Phase 3 trial for NAV4694,
subject to a maximum 10 % reduction of bonus if not achieved. |
| · | Realization of a specified amount in revenue from ‘business development’ sources such as in-licensing or partnering
milestone payments, subject to a maximum 15% reduction of bonus if not achieved. |
| · | Commencement of a Phase 1 or later stage clinical study for a Manocept platform product candidate, subject to a maximum 5%
reduction of bonus if not achieved. |
| · | Discretionary bonus, equal to 20% of the total bonus objective. |
For the Named Executive Officers, the following cash bonus targets
were established for fiscal 2014:
Named Executive Officer | |
Target Cash Bonus (% of Salary) | | |
Target Cash Bonus ($ Amount) | |
Mark J. Pykett, V.M.D., Ph.D. (a) | |
| 50.0 | % | |
$ | 199,500 | |
Ricardo J. Gonzalez (b) | |
| 50.0 | % | |
| 187,500 | |
Frederick O. Cope, Ph.D. | |
| 25.0 | % | |
| 69,783 | |
Brent L. Larson | |
| 27.5 | % | |
| 71,500 | |
Cornelia B. Reininger, M.D., Ph.D. (c) | |
| 30.0 | % | |
| 90,000 | |
Thomas H. Tulip, Ph.D. (d) | |
| 35.0 | % | |
| 109,900 | |
| (a) | Dr. Pykett separated from the Company effective May 30, 2014. No bonus was awarded to Dr. Pykett for fiscal 2014. |
| (b) | Mr. Gonzalez commenced employment with the Company effective October 13, 2014. The cash bonus awarded to Mr. Gonzalez for fiscal
2014 was pro-rated based on time served in his position. |
| (c) | Dr. Reininger separated from the Company effective May 31, 2015. No bonus was awarded to Dr. Reininger for fiscal 2014. |
| (d) | Dr. Tulip separated from the Company effective May 31, 2015. No bonus was awarded to Dr. Tulip for fiscal 2014. |
On March 3, 2015, the CNG Committee determined
the extent to which the Company’s goals were achieved during 2014. With respect to the first objective, (i) the Company did
not generate the specified revenue amounts derived directly from Lymphoseek during fiscal 2014, resulting in a 40% reduction in
the target bonus amount; (ii) approval of the sNDA for Lymphoseek for head and neck cancer evidenced successful achievement of
that goal; and (iii) ex-U.S. commercial launch activities in select countries were not initiated to the degree expected, resulting
in a 5% reduction in the target bonus amount. With regard to the second objective, the specified percentage of the total target
enrollment in the Company's NAV4-02 Phase 3 trial for NAV4694 was not achieved as originally intended due to the May 2014 realignment
of corporate objectives; however, the CNG Committee concluded that based on the accrual rate for brains that was achieved, there
would be no reduction in the target bonus amount. With respect to the third objective, the Company did not realize the specified
amount of revenue from ‘business development’ sources such as in-licensing or partnering milestone payments, resulting
in a 15% reduction in the target bonus amount. With regard to the fourth objective, commencement of a pilot study in subjects with
Kaposi's Sarcoma evidenced successful achievement of that goal. With respect to the discretionary portion of the total bonus opportunity,
the CNG Committee concluded, primarily due to the successful achievement of a second sNDA that significantly expanded the Lymphoseek
product label, that this component would be subject to no reduction of bonuses for non-executives, with the discretionary portion
of executive bonuses to be determined on a case-by-case basis by the CNG Committee. After reviewing the business performance objectives
and the related proposed payouts, the CNG Committee approved the total cash bonus payouts for each employee of the Company. The
approved cash bonus payouts to the Named Executive Officers, paid in March 2015, are shown under “Non-Equity Incentive Plan
Compensation” in the Summary Compensation table below.
On March 26, 2015, the CNG Committee established
the fiscal 2015 targets and performance measures for all Company employees. For fiscal 2015, the cash bonus for each executive
officer will be a function of the designated target bonus amount and certain business performance objectives, weighted as a percentage
of the total target amount. The business performance objectives established for fiscal 2015 are as follows:
| · | Achievement of a specified revenue amounts from Lymphoseek sales during fiscal 2015, subject to a maximum 65% reduction of
bonus if not achieved. |
| · | Adherence to corporate, departmental and project budgets to within a variance of +/- 5%, subject to maximum 15% reduction of
bonus if not achieved. |
| · | Initiation of enrollment in a clinical trial in support of Lymphoseek Life Cycle management in one of the following indications:
gynecological, genitourinary and/or gastrointestinal tumors, subject to a maximum 5% reduction of bonus if not achieved. |
| · | Achievement of the following goals related to Macrophage Therapeutics, subject to a maximum 5% reduction of bonus if not achieved: |
| o | Form and engage the scientific advisory board to inform disease target selection; and |
| o | Establish a development plan based on disease targets. |
| · | Discretionary bonus, equal to 10% of the total bonus objective. |
The CNG Committee approved the following
target cash bonus amounts for the Named Executive Officers for fiscal 2015: Mr. Gonzalez, $187,500; Dr. Cope, $97,696; and Mr.
Larson, $91,000. No target cash bonus amounts were approved for Dr. Reininger or Dr. Tulip due to their separation from the Company
in May 2015.
Long-Term Incentive Compensation.
All Company employees are eligible to receive equity awards in the form of stock options or restricted stock. Equity instruments
awarded under the Company’s equity-based compensation plan are based on the following criteria:
| · | Analysis of competitive information for comparable positions; |
| · | Evaluation of the value added to the Company by hiring or retaining specific employees; and |
| · | Each employee’s long-term potential contributions to our Company. |
Although equity awards may be made at any
time as determined by the CNG Committee, they are generally made to all full-time employees once per year or on the recipient’s
hire date in the case of new-hire grants.
The CNG Committee’s philosophy on
equity awards is that equity-based compensation is an effective method to align the interests of stockholders and management and
focus management’s attention on long-term results. When awarding equity-based compensation the CNG Committee considers the
impact the participant can have on our overall performance, strategic direction, financial results and stockholder value. Therefore,
equity awards are primarily based upon the participant’s position in the organization, competitive necessity and individual
performance. Equity awards for senior executives are determined as a percentage of base salary, based on published proxy data for
similar positions at peer group companies. Stock option awards have vesting schedules over several years to promote long-term performance
and retention of the recipient, and restricted stock awards may include specific performance criteria for vesting or vest over
a specified period of time.
In March 2015, the CNG Committee approved
the grant of options to purchase shares of common stock of the Company to full-time Company employees, including certain of the
Named Executive Officers. The stock options have an exercise price of $1.65, vest as to one-third of the shares on each of the
first three anniversaries of the date of grant, and expire on the tenth anniversary of the date of grant. If the employment of
the Named Executive Officer with the Company is terminated due to a change in control or without cause before all of the stock
options have vested, then pursuant to the terms of the stock option award agreement all stock options that have not vested at the
effective date of the Named Executive Officer’s termination shall immediately vest and become exercisable. The following
number of options was granted to each Named Executive Officer: Mr. Gonzalez, 0; Dr. Cope, 162,000; Mr. Larson, 151,000; Dr. Reininger,
0; and Dr. Tulip, 0.
Other Benefits and Perquisites. The
Named Executive Officers participate in other benefit plans on the same terms as other employees. These plans include medical,
dental, vision, disability and life insurance benefits, and our 401(k) retirement savings plan (the 401(k) Plan).
Our vacation policy allows employees to
carry up to 40 hours of unused vacation time forward to the next fiscal year. Any unused vacation time in excess of the amount
eligible for rollover is generally forfeited. However, from time to time, due to high demands on our employees during a given fiscal
year, we may elect to pay out for unused vacation time in excess of the amount eligible for rollover. The amount paid is calculated
based on the employee’s salary in effect at the end of the fiscal year to which the unused vacation time relates.
Our Named Executive Officers are considered
“key employees” for purposes of IRC Section 125 Plan non-discrimination testing. Based on such non-discrimination testing,
we determined that our Section 125 Plan was “top-heavy.” As such, our key employees are ineligible to participate in
the Section 125 Plan and are unable to pay their portion of medical, dental, and vision premiums on a pre-tax basis. As a result,
the Company reimburses its key employees an amount equal to the lost tax benefit.
We pay group life insurance premiums on
behalf of all employees, including the Named Executive Officers. The benefit provides life insurance coverage at two times the
employee’s annual salary plus $10,000, up to a maximum of $630,000.
We also pay group long-term disability insurance
premiums on behalf of all employees, including the Named Executive Officers. The benefit provides long-term disability insurance
coverage at 60% of the employee’s annual salary, up to a maximum of $10,000 per month, beginning 180 days after the date
of disability and continuing through age 65.
401(k) Retirement Plan. All employees
are given an opportunity to participate in our 401(k) Plan, following a new-hire waiting period. The 401(k) Plan allows participants
to have pre-tax amounts withheld from their pay and provides for a discretionary employer matching contribution (currently, a 40%
match up to 5% of salary in the form of our common stock). Participants may invest their contributions in various fund options,
but are prohibited from investing their contributions in our common stock. Participants are immediately vested in both their contributions
and Company matching contributions. The 401(k) Plan qualifies under section 401 of the Internal Revenue Code, which provides that
employee and company contributions and income earned on contributions are not taxable to the employee until withdrawn from the
Plan, and that we may deduct our contributions when made.
Employment Agreements
Our senior executive officers are employed
under employment agreements which specify the terms of their employment such as base salary, benefits, paid time off, and post-employment
benefits as shown in the tables below. Our employment agreements also specify that if a change in control occurs with respect to
our Company and the employment of a senior executive officer is concurrently or subsequently terminated:
| · | by the Company without cause (cause is defined to include any willful breach of a material duty by the senior executive officer
in the course of his or her employment or willful and continued neglect of his or her duty as an employee); |
| · | by the expiration of the term of the employment agreement; or |
| · | by the resignation of the senior executive officer because his or her title, authority, responsibilities, salary, bonus opportunities
or benefits have materially diminished, a material adverse change in his or her working conditions has occurred, his or her services
are no longer required in light of the Company’s business plan, or we breach the agreement; |
then, the senior executive officer would be paid a severance
payment as disclosed in the tables below. For purposes of such employment agreements, a change in control includes:
| · | the acquisition, directly or indirectly, by a person (other than our Company, an employee benefit plan established by the Board
of Directors, or a participant in a transaction approved by the Board of Directors for the principal purpose of raising additional
capital) of beneficial ownership of 30% or more of our securities with voting power in the next meeting of holders of voting securities
to elect the Directors; |
| · | a majority of the Directors elected at any meeting of the holders of our voting securities are persons who were not nominated
by our then current Board of Directors or an authorized committee thereof; |
| · | our stockholders approve a merger or consolidation of our Company with another person, other than a merger or consolidation
in which the holders of our voting securities outstanding immediately before such merger or consolidation continue to hold voting
securities in the surviving or resulting corporation (in the same relative proportions to each other as existed before such event)
comprising 80% or more of the voting power for all purposes of the surviving or resulting corporation; or |
| · | our stockholders approve a transfer of substantially all of our assets to another person other than a transfer to a transferee,
80% or more of the voting power of which is owned or controlled by us or by the holders of our voting securities outstanding immediately
before such transfer in the same relative proportions to each other as existed before such event. |
Mark J. Pykett, V.M.D., Ph.D. Prior
to his separation on May 30, 2014, Dr. Pykett was employed under a 20.5-month employment agreement effective through December 31,
2015. The employment agreement provided for an annual base salary of $399,000. For the calendar year ending December 31, 2014,
no cash bonus was paid to Dr. Pykett.
Ricardo J. Gonzalez. Mr. Gonzalez
is employed under a 36-month employment agreement effective through October 13, 2017. The employment agreement provides for an
annual base salary of $375,000. For the calendar year ending December 31, 2014, the CNG Committee awarded Mr. Gonzalez a cash bonus
of $16,241.
Frederick O. Cope, Ph.D. Dr. Cope
was employed under a 24-month employment agreement effective through December 31, 2014. The employment agreement provided for an
annual base salary of $271,000. Effective May 1, 2013, Dr. Cope’s annual base salary was increased to $279,130. For the calendar
year ending December 31, 2014, the CNG Committee awarded Dr. Cope a cash bonus of $27,913. Although Dr. Cope’s employment
agreement expired on December 31, 2014, the terms of the agreement provided for continuation of certain terms of the employment
agreement as long as Dr. Cope continues to be an employee of the Company following expiration of the agreement.
Brent L. Larson. Mr. Larson was employed
under a 24-month employment agreement effective through December 31, 2014. The employment agreement provided for an annual base
salary of $265,000. Effective May 1, 2013, Mr. Larson’s annual base salary was increased to $279,575. Effective January 1,
2014, Mr. Larson agreed to a reduction in his annual base salary to $260,000. For the calendar year ending December 31, 2014, the
CNG Committee awarded Mr. Larson a cash bonus of $17,875. Although Mr. Larson’s employment agreement expired on December
31, 2014, the terms of the agreement provided for continuation of certain terms of the employment agreement as long as Mr. Larson
continues to be an employee of the Company following expiration of the agreement.
Cornelia B. Reininger, M.D., Ph.D.
Prior to her separation on May 31, 2015, Dr. Reininger was employed under a 21-month employment agreement effective through December
31, 2015. The employment agreement provided for an annual base salary of $300,000. For the calendar year ending December 31, 2014,
the CNG Committee awarded no cash bonus to Dr. Reininger.
Thomas H. Tulip, Ph.D. Prior to his
separation on May 31, 2015, Dr. Tulip was employed under a 24-month employment agreement effective through May 31, 2014. The employment
agreement provided for an annual base salary of $325,000. Effective May 1, 2013, Dr. Tulip’s annual base salary was increased
to $339,625. Effective January 1, 2014, Dr. Tulip agreed to a reduction in his annual base salary to $314,000. For the calendar
year ending December 31, 2014, the CNG Committee awarded no cash bonus to Dr. Tulip. Although Dr. Tulip’s employment agreement
expired on May 31, 2014, the terms of the agreement provided for continuation of certain terms of the employment agreement as long
as Dr. Tulip continued to be an employee of the Company following expiration of the agreement.
Post-Employment Compensation
The following tables set forth the expected
benefit to be received by each of our Named Executive Officers in the event of his termination resulting from various scenarios,
assuming a termination date of December 31, 2014 and a stock price of $1.89, our closing stock price on December 31, 2014.
Mark J. Pykett, V.M.D., Ph.D.
Prior to his separation, Dr. Pykett was
employed under a 20.5-month employment agreement effective through December 31, 2015. Pursuant to the employment agreement, Dr.
Pykett served as our Chief Executive Officer until his separation from the Company. Effective May 30, 2014, the Company and Dr.
Pykett entered into a Separation Agreement and Release. Following the termination date, Dr. Pykett was entitled to receive (i)
a $750,000 severance payment, payable in two equal installments on June 9, 2014, and January 2, 2015, respectively; (ii) a single
payment for accrued vacation and personal days; and (iii) reimbursement for certain other expenses and fees. Certain of Dr. Pykett's
equity awards terminated upon separation, while others were modified in conjunction with the Separation Agreement and the Consulting
Agreement described below.
Effective June 1, 2014, the Company and
Dr. Pykett entered into a Consulting Agreement pursuant to which Dr. Pykett was to serve as an independent consultant to the Company
until December 31, 2014 with respect to clinical-regulatory activities, commercial activities, program management, and business
development, among other services. Dr. Pykett was entitled to a consulting fee of $27,500 per month plus reimbursement of reasonable
expenses. The Consulting Agreement also provided for a grant of 40,000 shares of restricted stock which were to vest upon certain
service and performance conditions.
Dr. Pykett terminated the Consulting Agreement
effective September 8, 2014. Certain of Dr. Pykett's equity awards were forfeited upon termination of the Consulting Agreement,
while others vested on December 1, 2014 due to achievement of certain goals during the period of the Consulting Agreement, in accordance
with the terms of the award agreements.
Ricardo J. Gonzalez
| |
For Cause
| | |
Resignation
| | |
Death
| | |
Disability
| | |
End of
Term | | |
Without
Cause | | |
Change in
Control | |
Cash payments: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Severance
(a) | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 375,000 | | |
$ | 375,000 | | |
$ | 750,000 | |
Disability supplement
(b) | |
| — | | |
| — | | |
| — | | |
| 185,100 | | |
| — | | |
| — | | |
| — | |
Paid time off (c) | |
| 7,212 | | |
| 7,212 | | |
| 7,212 | | |
| 7,212 | | |
| 7,212 | | |
| 7,212 | | |
| 7,212 | |
Continuation of benefits
(d) | |
| — | | |
| — | | |
| 74,608 | | |
| 74,608 | | |
| — | | |
| 74,608 | | |
| 74,608 | |
Stock
option vesting acceleration (e) | |
| — | | |
| — | | |
| — | | |
| — | | |
| 630,000 | | |
| 630,000 | | |
| 630,000 | |
Total | |
$ | 7,212 | | |
$ | 7,212 | | |
$ | 81,820 | | |
$ | 266,920 | | |
$ | 1,012,212 | | |
$ | 1,086,820 | | |
$ | 1,461,820 | |
| (a) | Severance amounts are pursuant to Mr. Gonzalez’s employment agreement. |
| (b) | During the first 6 months of disability, the Company will supplement disability insurance payments to Mr. Gonzalez to achieve
100% salary replacement. The Company’s short-term disability insurance policy currently pays $100 per week for a maximum
of 24 weeks. |
| (c) | Amount represents the value of 40 hours of accrued but unused vacation time as of December 31, 2014. |
| (d) | Amount represents 34 months of medical, dental and vision insurance premiums at rates in effect at December 31, 2014. |
| (e) | Pursuant to Mr. Gonzalez’s stock option agreement, all unvested stock options outstanding will vest upon termination
at the end of the term of his employment agreement, termination without cause, or a change in control. Amount represents the value
of the stock at $1.89, the closing price of the Company’s stock on December 31, 2014, less the exercise price of the options. |
Frederick O. Cope, Ph.D.
| |
For Cause | | |
Resignation | | |
Death | | |
Disability | | |
End of Term | | |
Without Cause | | |
Change in Control | |
Cash payments: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Severance (a) | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 245,000 | | |
$ | 245,000 | | |
$ | 367,500 | |
Disability supplement (b) | |
| — | | |
| — | | |
| — | | |
| 137,165 | | |
| — | | |
| — | | |
| — | |
Paid time off (c) | |
| 5,368 | | |
| 5,368 | | |
| 5,368 | | |
| 5,368 | | |
| 5,368 | | |
| 5,368 | | |
| 5,368 | |
2014 401(k) match (d) | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | |
Continuation of benefits (e) | |
| — | | |
| — | | |
| 18,528 | | |
| 18,528 | | |
| — | | |
| 18,528 | | |
| 18,528 | |
Stock option vesting acceleration (f) | |
| — | | |
| — | | |
| — | | |
| — | | |
| 15,960 | | |
| 15,960 | | |
| 15,960 | |
Restricted stock vesting
acceleration (g) | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 94,450 | |
Total | |
$ | 10,568 | | |
$ | 10,568 | | |
$ | 29,096 | | |
$ | 166,261 | | |
$ | 271,528 | | |
$ | 290,056 | | |
$ | 507,006 | |
| (a) | Severance amounts are pursuant to Dr. Cope’s employment agreement. |
| (b) | During the first 6 months of disability, the Company will supplement disability insurance payments to Dr. Cope to achieve 100%
salary replacement. The Company’s short-term disability insurance policy currently pays $100 per week for a maximum of 24
weeks. |
| (c) | Amount represents the value of 40 hours of accrued but unused vacation time as of December 31, 2014. |
| (d) | Amount represents the value of 2,858 shares of Company stock which was accrued during 2014 as the Company’s 401(k) matching
contribution but was unissued as of December 31, 2014. |
| (e) | Amount represents 12 months of medical, dental and vision insurance premiums at rates in effect at December 31, 2014. |
| (f) | Pursuant to Dr. Cope’s stock option agreements, all unvested stock options outstanding will vest upon termination at
the end of the term of his employment agreement, termination without cause, or a change in control. Amount represents the value
of the stock at $1.89, the closing price of the Company’s stock on December 31, 2014, less the exercise price of the options.
Amount does not include stock options with an exercise price higher than $1.89, the closing price of the Company’s stock
on December 31, 2014. |
| (g) | Pursuant to Dr. Cope’s restricted stock agreements, certain unvested restricted stock outstanding will vest upon a change
in control. |
Brent L. Larson
| |
For Cause | | |
Resignation | | |
Death | | |
Disability | | |
End of Term | | |
Without Cause | | |
Change in Control | |
Cash payments: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Severance (a) | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 207,000 | | |
$ | 207,000 | | |
$ | 310,500 | |
Disability supplement (b) | |
| — | | |
| — | | |
| — | | |
| 127,600 | | |
| — | | |
| — | | |
| — | |
Paid time off (c) | |
| 5,000 | | |
| 5,000 | | |
| 5,000 | | |
| 5,000 | | |
| 5,000 | | |
| 5,000 | | |
| 5,000 | |
2014 401(k) match (d) | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | |
Continuation of benefits (e) | |
| — | | |
| — | | |
| 26,332 | | |
| 26,332 | | |
| — | | |
| 26,332 | | |
| 26,332 | |
Stock option vesting acceleration
(f) | |
| — | | |
| — | | |
| — | | |
| — | | |
| 14,880 | | |
| 14,880 | | |
| 14,880 | |
Total | |
$ | 10,200 | | |
$ | 10,200 | | |
$ | 36,532 | | |
$ | 164,132 | | |
$ | 232,080 | | |
$ | 258,412 | | |
$ | 361,912 | |
| (a) | Severance amounts are pursuant to Mr. Larson’s employment agreement. |
| (b) | During the first 6 months of disability, the Company will supplement disability insurance payments to Mr. Larson to achieve
100% salary replacement. The Company’s short-term disability insurance policy currently pays $100 per week for a maximum
of 24 weeks. |
| (c) | Amount represents the value of 40 hours of accrued but unused vacation time as of December 31, 2014. |
| (d) | Amount represents the value of 2,984 shares of Company stock which was accrued during 2014 as the Company’s 401(k) matching
contribution but was unissued as of December 31, 2014. |
| (e) | Amount represents 12 months of medical, dental and vision insurance premiums at rates in effect at December 31, 2014. |
| (f) | Pursuant to Mr. Larson’s stock option agreements, all unvested stock options outstanding will vest upon termination at
the end of the term of his employment agreement, termination without cause, or a change in control. Amount represents the value
of the stock at $1.89, the closing price of the Company’s stock on December 31, 2014, less the exercise price of the options.
Amount does not include stock options with an exercise price higher than $1.89, the closing price of the Company’s stock
on December 31, 2014. |
Cornelia B. Reininger, M.D., Ph.D. (g)
| |
For Cause | | |
Resignation | | |
Death | | |
Disability | | |
End of
Term | | |
Without Cause | | |
Change in Control | |
Cash payments: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Severance (a) | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 300,000 | | |
$ | 300,000 | | |
$ | 450,000 | |
Disability supplement (b) | |
| — | | |
| — | | |
| — | | |
| 147,600 | | |
| — | | |
| — | | |
| — | |
Paid time off (c) | |
| 5,769 | | |
| 5,769 | | |
| 5,769 | | |
| 5,769 | | |
| 5,769 | | |
| 5,769 | | |
| 5,769 | |
2014 401(k) match (d) | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | |
Continuation of benefits (e) | |
| — | | |
| — | | |
| 11,652 | | |
| 11,652 | | |
| — | | |
| 11,652 | | |
| 11,652 | |
Stock option vesting acceleration
(f) | |
| — | | |
| — | | |
| — | | |
| — | | |
| 17,160 | | |
| 17,160 | | |
| 17,160 | |
Total | |
$ | 10,969 | | |
$ | 10,969 | | |
$ | 22,621 | | |
$ | 170,221 | | |
$ | 328,129 | | |
$ | 339,781 | | |
$ | 489,781 | |
| (a) | Severance amounts are pursuant to Dr. Reininger's employment agreement. |
| (b) | During the first 6 months of disability, the Company will supplement disability insurance payments to Dr. Reininger to achieve
100% salary replacement. The Company’s short-term disability insurance policy currently pays $100 per week for a maximum
of 24 weeks. |
| (c) | Amount represents the value of 40 hours of accrued but unused vacation time as of December 31, 2014. |
| (d) | Amount represents the value of 2,747 shares of Company stock which was accrued during 2014 as the Company’s 401(k) matching
contribution but was unissued as of December 31, 2014. |
| (e) | Amount represents 12 months of medical, dental and vision insurance premiums at rates in effect at December 31, 2014. |
| (f) | Pursuant to Dr. Reininger’s stock option agreements, all unvested stock options outstanding will vest upon termination
at the end of the term of his employment agreement, termination without cause, or a change in control. Amount represents the value
of the stock at $1.89, the closing price of the Company’s stock on December 31, 2014, less the exercise price of the options.
Amount does not include stock options with an exercise price higher than $1.89, the closing price of the Company’s stock
on December 31, 2014. |
| (g) | Effective May 31, 2015, the Company and Dr. Reininger entered into a Separation and Release Agreement. Following the termination
date, Dr. Reininger is entitled to receive (i) a $300,000 severance payment; (ii) a single payment of $8,004 for continuation of
her car allowance for 12 months, (iii) a single payment of $5,514 for continuation of her health benefits for 12 months; and (iv)
a single payment of $6,346 for accrued vacation time. All of Dr. Reininger’s stock option awards vested upon separation,
and will expire 90 days following the date of separation. |
Thomas H. Tulip, Ph.D. (h)
| |
For Cause | | |
Resignation | | |
Death | | |
Disability | | |
End of
Term | | |
Without
Cause | | |
Change in
Control | |
Cash payments: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Severance (a) | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 325,000 | | |
$ | 325,000 | | |
$ | 487,500 | |
Disability supplement (b) | |
| — | | |
| — | | |
| — | | |
| 154,600 | | |
| — | | |
| — | | |
| — | |
Paid time off (c) | |
| 6,038 | | |
| 6,038 | | |
| 6,038 | | |
| 6,038 | | |
| 6,038 | | |
| 6,038 | | |
| 6,038 | |
2014 401(k) match (d) | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | | |
| 5,200 | |
Continuation of benefits (e) | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
Stock option vesting acceleration (f) | |
| — | | |
| — | | |
| — | | |
| — | | |
| 18,000 | | |
| 18,000 | | |
| 18,000 | |
Restricted stock vesting acceleration (g) | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
Total | |
$ | 11,238 | | |
$ | 11,238 | | |
$ | 11,238 | | |
$ | 165,838 | | |
$ | 354,238 | | |
$ | 354,238 | | |
$ | 516,738 | |
| (a) | Severance amounts are pursuant to Dr. Tulip’s employment agreement. |
| (b) | During the first 6 months of disability, the Company will supplement disability insurance payments to Dr. Tulip to achieve
100% salary replacement. The Company’s short-term disability insurance policy currently pays $100 per week for a maximum
of 24 weeks. |
| (c) | Amount represents the value of 40 hours of accrued but unused vacation time as of December 31, 2014. |
| (d) | Amount represents the value of 2,720 shares of Company stock which was accrued during 2014 as the Company’s 401(k) matching
contribution but was unissued as of December 31, 2014. |
| (e) | Dr. Tulip did not participate in the Company’s medical, dental or vision insurance plans as of December 31, 2014. |
| (f) | Pursuant to Dr. Tulip’s stock option agreements, all unvested stock options outstanding will vest upon termination at
the end of the term of his employment agreement, termination without cause, or a change in control. Amount represents the value
of the stock at $1.89, the closing price of the Company’s stock on December 31, 2014, less the exercise price of the options.
Amount does not include stock options with an exercise price higher than $1.89, the closing price of the Company’s stock
on December 31, 2014. |
| (g) | Dr. Tulip’s restricted stock agreements do not include provisions for accelerated vesting. |
| (h) | Effective May 31, 2015, the Company and Dr. Tulip entered into a Separation and Release Agreement. Following the termination
date, Dr. Tulip is entitled to receive (i) a $325,000 severance payment; (ii) a single payment of $11,009 for continuation of his
health benefits for 12 months; and (iii) a single payment of $24,154 for accrued vacation time. All of Dr. Tulip’s stock
option awards vested upon separation, and will expire 90 days following the date of separation. All of Dr. Tulip’s unvested
restricted stock was forfeited. |
Report of Compensation, Nominating and Governance Committee
The CNG Committee is responsible for establishing,
reviewing and approving the Company’s compensation philosophy and policies, reviewing and making recommendations to the Board
regarding forms of compensation provided to the Company’s directors and officers, reviewing and determining cash and equity
awards for the Company’s officers and other employees, and administering the Company’s equity incentive plans.
In this context, the CNG Committee has reviewed
and discussed with management the Compensation Discussion and Analysis included in this proxy statement for the Annual Meeting.
In reliance on the review and discussions referred to above, the CNG Committee recommended to the Board, and the Board has approved,
that the Compensation Discussion and Analysis be included in this proxy statement for filing with the SEC.
|
The Compensation, Nominating |
|
and Governance Committee |
|
|
|
Peter F. Drake, Ph.D. (Chairman) |
|
Perry A. Karsen |
|
Gordon A. Troup |
Compensation, Nominating and Governance Committee Interlocks
and Insider Participation
The current members of our CNG Committee
are: Peter F. Drake, Ph.D. (Chairman), Perry A. Karsen, and Gordon A. Troup, and each served as a member of the CNG Committee during
the last completed fiscal year. None of these individuals were at any time during the fiscal year ended December 31, 2014, or at
any other time, an officer or employee of the Company.
No director who served on the CNG Committee
during 2014 had any relationships requiring disclosure by the Company under the SEC’s rules requiring disclosure of certain
relationships and related-party transactions. None of the Company’s executive officers served as a director or a member of
a compensation committee (or other committee serving an equivalent function) of any other entity, the executive officers of which
served as a director of the Company or member of the CNG Committee during 2014.
Summary Compensation Table
The following table sets forth certain information
concerning the annual and long-term compensation of our Named Executive Officers for the last three fiscal years.
Summary Compensation Table for Fiscal
2014
Named Executive Officer | |
Year | |
Salary | | |
(a) Stock
Awards | | |
(b) Option
Awards | | |
(c) Non-Equity Incentive Plan
Compensation | | |
(d) All Other
Compensation | | |
Total Compensation | |
Mark J. Pykett, V.M.D., Ph.D. (e) | |
2014 | |
$ | 166,250 | | |
$ | — | | |
$ | 279,468 | | |
$ | — | | |
$ | 411,669 | | |
$ | 857,387 | |
Chief Executive Officer | |
2013 | |
| 433,500 | | |
| — | | |
| 557,448 | | |
| 127,500 | | |
| 6,749 | | |
| 1,125,197 | |
| |
2012 | |
| 425,000 | | |
| 983,700 | | |
| 385,462 | | |
| 140,250 | | |
| 13,808 | | |
| 1,948,220 | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Ricardo J. Gonzalez (f) | |
2014 | |
$ | 82,452 | | |
$ | — | | |
$ | 768,247 | | |
$ | 16,241 | | |
$ | — | | |
$ | 866,940 | |
President and Chief Executive Officer | |
2013 | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
| |
2012 | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Frederick O. Cope, Ph.D. | |
2014 | |
$ | 279,130 | | |
$ | — | | |
$ | 144,067 | | |
$ | 27,913 | | |
$ | 6,173 | | |
$ | 457,283 | |
Senior Vice President and | |
2013 | |
| 276,420 | | |
| — | | |
| 265,888 | | |
| 50,813 | | |
| 6,179 | | |
| 599,300 | |
Chief Scientific Officer | |
2012 | |
| 271,000 | | |
| — | | |
| 244,768 | | |
| 55,043 | | |
| 11,114 | | |
| 581,925 | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Brent L. Larson | |
2014 | |
$ | 260,000 | | |
$ | — | | |
$ | 134,318 | | |
$ | 17,875 | | |
$ | 6,727 | | |
$ | 418,920 | |
Executive Vice President and | |
2013 | |
| 274,717 | | |
| — | | |
| 260,387 | | |
| 51,013 | | |
| 6,847 | | |
| 592,964 | |
Chief Financial Officer | |
2012 | |
| 265,000 | | |
| — | | |
| 169,603 | | |
| 49,555 | | |
| 11,404 | | |
| 495,562 | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Cornelia B. Reininger, M.D., Ph.D. (g) | |
2014 | |
$ | 300,000 | | |
$ | — | | |
$ | 154,899 | | |
$ | — | | |
$ | 13,652 | | |
$ | 468,551 | |
Senior Vice President and | |
2013 | |
| 300,000 | | |
| — | | |
| 220,045 | | |
| 67,500 | | |
| 98,087 | | |
| 685,632 | |
Chief Medical Officer | |
2012 | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Thomas H. Tulip, Ph.D. (h) | |
2014 | |
$ | 314,000 | | |
$ | — | | |
$ | 162,481 | | |
$ | — | | |
$ | 6,200 | | |
$ | 482,681 | |
President and | |
2013 | |
| 334,750 | | |
| — | | |
| 319,066 | | |
| 71,094 | | |
| 6,000 | | |
| 730,910 | |
Chief Business Officer | |
2012 | |
| 314,583 | | |
| — | | |
| 314,151 | | |
| 75,075 | | |
| 9,615 | | |
| 713,424 | |
| (a) | Amount represents the aggregate grant date fair value in accordance with FASB ASC Topic 718. Assumptions made in the valuation
of stock awards are disclosed in Note 1(e) of the Notes to the Consolidated Financial Statements in the Company’s Form 10-K
filed March 16, 2015. |
| (b) | Amount represents the aggregate grant date fair value in accordance with FASB ASC Topic 718. Assumptions made in the valuation
of option awards are disclosed in Note 1(e) of the Notes to the Consolidated Financial Statements in the Company’s Form 10-K
filed March 16, 2015. |
| (c) | Amount represents the cash bonuses which have been approved by the CNG Committee and are disclosed for the year in which they
were earned (i.e., the year to which the service relates). |
| (d) | Amount represents additional compensation as disclosed in the All Other Compensation table below. |
| (e) | Dr. Pykett separated from the Company effective May 30, 2014. |
| (f) | Mr. Gonzalez commenced employment with the Company effective October 13, 2014. |
| (g) | Dr. Reininger commenced employment with the Company effective November 1, 2012, and separated from the Company effective May
31, 2015. |
| (h) | Dr. Tulip separated from the Company effective May 31, 2015. |
All Other Compensation
The following table describes each component
of the amounts shown in the “All Other Compensation” column in the Summary Compensation table above.
All Other Compensation Table for Fiscal
2014
Named Executive Officer | |
Year | |
(a) Payment for Unused Vacation | | |
(b) Reimbursement of Additional Tax Liability Related to Health Insurance Premiums | | |
(c) 401(k) Plan Employer Matching Contribution | | |
Other | | |
Total All Other Compensation | |
Mark J. Pykett, V.M.D., Ph.D. | |
2014 | |
$ | 32,277 | | |
$ | 471 | | |
$ | 3,921 | | |
$ | 375,000 | (d) | |
$ | 411,669 | |
| |
2013 | |
| — | | |
| 1,749 | | |
| 5,000 | | |
| — | | |
| 6,749 | |
| |
2012 | |
| 7,212 | | |
| 1,596 | | |
| 5,000 | | |
| — | | |
| 13,808 | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Ricardo J. Gonzalez | |
2014 | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | |
| |
2013 | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
| |
2012 | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Frederick O. Cope, Ph.D. | |
2014 | |
$ | — | | |
$ | 973 | | |
$ | 5,200 | | |
$ | — | | |
$ | 6,173 | |
| |
2013 | |
| — | | |
| 1,179 | | |
| 5,000 | | |
| — | | |
| 6,179 | |
| |
2012 | |
| 5,096 | | |
| 1,018 | | |
| 5,000 | | |
| — | | |
| 11,114 | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Brent L. Larson | |
2014 | |
$ | — | | |
$ | 1,527 | | |
$ | 5,200 | | |
$ | — | | |
$ | 6,727 | |
| |
2013 | |
| — | | |
| 1,847 | | |
| 5,000 | | |
| — | | |
| 6,847 | |
| |
2012 | |
| 4,808 | | |
| 1,596 | | |
| 5,000 | | |
| — | | |
| 11,404 | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Cornelia B. Reininger, M.D., Ph.D. | |
2014 | |
$ | — | | |
$ | 448 | | |
$ | 5,200 | | |
$ | 8,004 | (e) | |
$ | 13,652 | |
| |
2013 | |
| — | | |
| 112 | | |
| 5,000 | | |
| 92,975 | (f) | |
| 98,087 | |
| |
2012 | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Thomas H. Tulip, Ph.D. | |
2014 | |
$ | — | | |
$ | — | | |
$ | 5,200 | | |
$ | 1,000 | (g) | |
$ | 6,200 | |
| |
2013 | |
| — | | |
| — | | |
| 5,000 | | |
| 1,000 | (g) | |
| 6,000 | |
| |
2012 | |
| 4,615 | | |
| — | | |
| 5,000 | | |
| — | | |
| 9,615 | |
| (a) | Amount represents payment for unused vacation time in excess of the amount eligible for rollover in a fiscal year, or payment
for unused vacation time upon separation from the Company. The amount paid is calculated based on the employee’s salary in
effect at the end of the period to which the unused vacation time relates. |
| (b) | Amount represents reimbursement of the lost tax benefit due to the ineligibility of our Named Executive Officers to pay their
portion of medical, dental, and vision premiums on a pre-tax basis under our IRC Section 125 Plan. |
| (c) | Amount represents the value of the common stock contributed to the Named Executive Officer’s account in our 401(k) Plan
as calculated on a quarterly basis. |
| (d) | Amount represents Dr. Pykett's first separation payment in accordance with his Separation Agreement and Release dated May 30,
2014. |
| (e) | Amount represents Dr. Reininger's car allowance payments. |
| (f) | Amount represents Dr. Reininger's moving expenses to relocate from Germany to the U.S. of $58,827, reimbursement of additional
income taxes on the value of the moving expenses of $12,857, immigration-related legal fees of $11,953 and car allowance payments
totaling $9,338. |
| (g) | Amount represents Dr. Tulip's additional bonus paid for non-participation in the Company’s medical, dental, and vision
plans. |
Grants of Plan-Based Awards
The following table sets forth certain information
about plan-based awards that we made to the Named Executive Officers during fiscal 2014. For information about the plans under
which these awards were granted, see the discussion under “Short-Term Incentive Compensation” and “Long-Term
Incentive Compensation” in the “Compensation Discussion and Analysis” section above.
Grants of Plan-Based
Awards Table for Fiscal 2014
| |
| |
Estimated
Future Payouts
Under Non-Equity
Incentive Plan
Awards (a) | | |
Estimated
Future Payouts
Under Equity
Incentive Plan
Awards | | |
All
Other Stock Awards: Number | | |
All
Other Option Awards: Number
of Securities | | |
Exercise Price
of | | |
Grant
Date Fair
Value of
Stock and
| |
Named Executive
Officer | |
Grant
Date | |
Threshold | | |
Maximum | | |
Threshold | | |
Maximum | | |
of
Shares of
Stock | | |
Underlying Options | | |
Option Awards | | |
Option Awards | |
Mark J. Pykett, | |
N/A | |
$ | — | | |
$ | 199,500 | | |
| — | | |
| — | | |
| — | | |
| — | | |
$ | — | | |
$ | — | (a) |
V.M.D., Ph.D. | |
1/28/2014 | |
$ | — | | |
$ | — | | |
| — | | |
| — | | |
| — | | |
| 258,000 | | |
$ | 1.77 | | |
$ | 279,468 | (b) |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Ricardo J. | |
N/A | |
$ | — | | |
$ | 187,500 | | |
| — | | |
| — | | |
| — | | |
| — | | |
$ | — | | |
$ | — | (a) |
Gonzalez | |
10/13/2014 | |
$ | — | | |
$ | — | | |
| — | | |
| — | | |
| — | | |
| 1,000,000 | | |
$ | 1.26 | | |
$ | 768,247 | (c) |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Frederick O. Cope, | |
N/A | |
$ | — | | |
$ | 69,783 | | |
| — | | |
| — | | |
| — | | |
| — | | |
$ | — | | |
$ | — | (a) |
Ph.D. | |
1/28/2014 | |
$ | — | | |
$ | — | | |
| — | | |
| — | | |
| — | | |
| 133,000 | | |
$ | 1.77 | | |
$ | 144,067 | (b) |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Brent L. Larson | |
N/A | |
$ | — | | |
$ | 71,500 | | |
| — | | |
| — | | |
| — | | |
| — | | |
$ | — | | |
$ | — | (a) |
| |
1/28/2014 | |
$ | — | | |
$ | — | | |
| — | | |
| — | | |
| — | | |
| 124,000 | | |
$ | 1.77 | | |
$ | 134,318 | (b) |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Cornelia B. Reininger, | |
N/A | |
$ | — | | |
$ | 90,000 | | |
| — | | |
| — | | |
| — | | |
| — | | |
$ | — | | |
$ | — | (a) |
M.D., Ph.D. | |
1/28/2014 | |
$ | — | | |
$ | — | | |
| — | | |
| — | | |
| — | | |
| 143,000 | | |
$ | 1.77 | | |
$ | 154,899 | (b) |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Thomas H. Tulip, | |
N/A | |
$ | — | | |
$ | 109,900 | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
$ | — | (a) |
Ph.D. | |
1/28/2014 | |
$ | — | | |
$ | — | | |
| — | | |
| — | | |
| — | | |
| 150,000 | | |
$ | 1.77 | | |
$ | 162,481 | (b) |
| (a) | The threshold amount reflects the fact that no cash bonus awards would have been payable if none of the specified business
performance objectives were achieved. The maximum amount reflects the target cash bonus awards payable if all of the specified
business performance objectives are achieved. For actual cash bonus award amounts, see the “Non-Equity Incentive Plan Compensation”
column in the Summary Compensation table above. |
| (b) | These stock options vest as to one-fourth on each of the first four anniversaries of the date of grant, and expire on the tenth
anniversary of the date of grant. If the employment of the Named Executive Officer with the Company is terminated due to a change
in control or without cause before all of the stock options have vested, then pursuant to the terms of the Stock Option Award Agreements
all stock options that have not vested at the effective date of the Named Executive Officer’s termination shall immediately
vest and become exercisable. |
| (c) | These stock options shall vest and become exercisable in three tranches, provided that Mr. Gonzalez has been an employee of
the Company continuously from the date of grant through the date when such portion of the option vests. The first tranche of 300,000
options will vest and become exercisable on the first anniversary of the date of grant. The second tranche of 300,000 options will
vest and become exercisable on or after the second anniversary of the date of grant, provided that the options will not be exercisable
with respect to such shares unless and until the average closing price per share of the Company’s common stock for the ten
trading days prior to exercise equals or exceeds $2.50 per share. The third tranche of 400,000 options will vest and become exercisable
on or after the third anniversary of the date of grant, provided that the options will not be exercisable with respect to such
shares unless and until the average closing price per share of the Company’s common stock for the ten trading days prior
to exercise equals or exceeds $3.50 per share. |
Outstanding Equity Awards
The following table presents certain information
concerning outstanding equity awards held by the Named Executive Officers as of December 31, 2014.
Outstanding Equity Awards Table at Fiscal
2014 Year-End
| |
Option Awards | |
Stock Awards |
| |
| | |
| | |
| |
| |
| | |
| | |
Equity Incentive
Plan Awards
|
| |
Number
of Securities Underlying
Unexercised Options
(#) | | |
Option | | |
Option | |
| |
Number
of Shares
of Stock
that | | |
Market
Value of
Shares of Stock that | | |
Number
of | | |
Market
Value of | | |
|
Named Executive
Officer | |
Exercisable | | |
Unexercisable | | |
Exercise Price | | |
Expiration Date | |
Note | |
Have
Not Vested | | |
Have
Not Vested | | |
Unearned Shares | | |
Unearned Shares
(p) | | |
Note |
Mark J. Pykett, | |
| | | |
| | | |
| | | |
| |
| |
| | | |
| | | |
| | | |
| | | |
|
V.M.D., Ph.D. | |
| | | |
| | | |
| | | |
| |
| |
| | | |
| | | |
| | | |
| | | |
|
| |
| | | |
| | | |
| | | |
| |
| |
| | | |
| | | |
| | | |
| | | |
|
Ricardo J. Gonzalez | |
| — | | |
| 1,000,000 | | |
$ | 1.26 | | |
10/13/2024 | |
(m) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| | | |
| | | |
| | | |
| |
| |
| | | |
| | | |
| | | |
| | | |
|
Frederick O. Cope, | |
| 50,000 | | |
| — | | |
$ | 0.65 | | |
2/16/2019 | |
(e) | |
| | | |
| | | |
| 50,000 | | |
$ | 94,500 | | |
(n) |
Ph.D. | |
| 75,000 | | |
| — | | |
$ | 1.10 | | |
10/30/2019 | |
(f) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| 120,000 | | |
| — | | |
$ | 1.90 | | |
12/21/2020 | |
(g) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| 63,500 | | |
| 63,500 | | |
$ | 3.28 | | |
2/17/2022 | |
(i) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| 36,250 | | |
| 108,750 | | |
$ | 3.08 | | |
2/15/2023 | |
(k) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| — | | |
| 133,000 | | |
$ | 1.77 | | |
1/28/2024 | |
(l) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| | | |
| | | |
| | | |
| |
| |
| | | |
| | | |
| | | |
| | | |
|
Brent L. Larson | |
| 40,000 | | |
| — | | |
$ | 0.26 | | |
12/27/2015 | |
(a) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| 50,000 | | |
| — | | |
$ | 0.27 | | |
12/15/2016 | |
(b) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| 50,000 | | |
| — | | |
$ | 0.362 | | |
1/3/2018 | |
(c) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| 25,000 | | |
| — | | |
$ | 0.59 | | |
1/5/2019 | |
(d) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| 75,000 | | |
| — | | |
$ | 1.10 | | |
10/30/2019 | |
(f) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| 95,000 | | |
| — | | |
$ | 1.90 | | |
12/21/2020 | |
(g) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| 44,000 | | |
| 44,000 | | |
$ | 3.28 | | |
2/17/2022 | |
(i) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| 35,500 | | |
| 106,500 | | |
$ | 3.08 | | |
2/15/2023 | |
(k) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| — | | |
| 124,000 | | |
$ | 1.77 | | |
1/28/2024 | |
(l) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| | | |
| | | |
| | | |
| |
| |
| | | |
| | | |
| | | |
| | | |
|
Cornelia B. Reininger, | |
| 44,000 | | |
| 44,000 | | |
$ | 2.85 | | |
11/1/2022 | |
(j) | |
| | | |
| | | |
| | | |
| | | |
|
M.D., Ph.D. (q) | |
| 30,000 | | |
| 90,000 | | |
$ | 3.08 | | |
2/15/2023 | |
(k) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| — | | |
| 143,000 | | |
$ | 1.77 | | |
1/28/2024 | |
(l) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| | | |
| | | |
| | | |
| |
| |
| | | |
| | | |
| | | |
| | | |
|
Thomas H. Tulip, | |
| 82,500 | | |
| 27,500 | | |
$ | 4.93 | | |
6/1/2021 | |
(h) | |
| | | |
| | | |
| 40,000 | | |
$ | 75,600 | | |
(o) |
Ph.D. (r) | |
| 81,500 | | |
| 81,500 | | |
$ | 3.28 | | |
2/17/2022 | |
(i) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| 43,500 | | |
| 130,500 | | |
$ | 3.08 | | |
2/15/2023 | |
(k) | |
| | | |
| | | |
| | | |
| | | |
|
| |
| — | | |
| 150,000 | | |
$ | 1.77 | | |
1/28/2024 | |
(l) | |
| | | |
| | | |
| | | |
| | | |
|
| (a) | Options were granted 12/27/2005 and vested as to one-third immediately and on each of the first two anniversaries of the date
of grant. |
| (b) | Options were granted 12/15/2006 and vested as to one-third on each of the first three anniversaries of the date of grant. |
| (c) | Options were granted 1/3/2008 and vested as to one-third on each of the first three anniversaries of the date of grant. |
| (d) | Options were granted 1/5/2009 and vested as to one-third on each of the first three anniversaries of the date of grant. |
| (e) | Options were granted 2/16/2009 and vested as to one-third on each of the first three anniversaries of the date of grant. |
| (f) | Options were granted 10/30/2009 and vested as to one-third on each of the first three anniversaries of the date of grant. |
| (g) | Options were granted 12/21/2010 and vest as to one-fourth on each of the first four anniversaries of the date of grant. |
| (h) | Options were granted 6/1/2011 and vest as to one-fourth on each of the first four anniversaries of the date of grant. |
| (i) | Options were granted 2/17/2012 and vest as to one-fourth on each of the first four anniversaries of the date of grant. |
| (j) | Options were granted 11/1/2012 and vest as to one-fourth on each of the first four anniversaries of the date of grant. |
| (k) | Options were granted 2/15/2013 and vest as to one-fourth on each of the first four anniversaries of the date of grant. |
| (l) | Options were granted 1/28/2014 and vest as to one-fourth on each of the first four anniversaries of the date of grant. |
| (m) | Options were granted 10/13/2014 and shall vest and become exercisable in three tranches, provided that Mr. Gonzalez has been
an employee of the Company continuously from the date of grant through the date when such portion of the option vests. The first
tranche of 300,000 options will vest and become exercisable on the first anniversary of the date of grant. The second tranche of
300,000 options will vest and become exercisable on or after the second anniversary of the date of grant, provided that the options
will not be exercisable with respect to such shares unless and until the average closing price per share of the Company’s
common stock for the ten trading days prior to exercise equals or exceeds $2.50 per share. The third tranche of 400,000 options
will vest and become exercisable on or after the third anniversary of the date of grant, provided that the options will not be
exercisable with respect to such shares unless and until the average closing price per share of the Company’s common stock
for the ten trading days prior to exercise equals or exceeds $3.50 per share. |
| (n) | Restricted shares granted February 16, 2009. Pursuant to the terms of the restricted stock agreement between the Company and
Dr. Cope, the restricted shares will vest upon the commencement of patient enrollment in a Phase 3 clinical trial in humans of
NAV1800. All of the restricted shares vest upon the occurrence of a change in control as defined in Dr. Cope’s employment
agreement. If the employment of Dr. Cope with the Company is terminated for reasons other than a change in control before all of
the restricted shares have vested, then pursuant to the terms of the restricted stock agreement all restricted shares that have
not vested at the effective date of Dr. Cope’s termination shall immediately be forfeited by Dr. Cope. |
| (o) | Restricted shares granted June 1, 2011. Pursuant to the terms of the restricted stock agreement between the Company and Dr.
Tulip, 20,000 of the restricted shares will vest upon the partnering of Lymphoseek in Europe covering at least four countries,
and 20,000 will vest upon the achievement of annual revenue to the Company from Cardinal Health, Inc. related to Lymphoseek of
over $2 million per month for three consecutive months following the receipt of commercial marketing clearance in the U.S., if
achieved before the 24th month following such marketing clearance. Dr. Tulip’s restricted stock agreements do not include
provisions for accelerated vesting. If the employment of Dr. Tulip with the Company is terminated before all of the restricted
shares have vested, then pursuant to the terms of the restricted stock agreement all restricted shares that have not vested at
the effective date of Dr. Tulip’s termination shall immediately be forfeited by Dr. Tulip. |
| (p) | Estimated by reference to the closing market price of the Company’s common stock on December 31, 2014, pursuant to Instruction
3 to Item 402(p)(2) of Regulation S-K. The closing price of the Company’s common stock on December 31, 2014, was $1.89. |
| (q) | Dr. Reininger separated from the Company effective May 31, 2015. All of Dr. Reininger’s stock option awards vested upon
separation, and will expire 90 days following the date of separation. |
| (r) | Dr. Tulip separated from the Company effective May 31, 2015. All of Dr. Tulip’s stock option awards vested upon separation,
and will expire 90 days following the date of separation. All of Dr. Tulip’s unvested restricted stock was forfeited. |
Options Exercised and Stock Vested
The following table presents, with respect
to the Named Executive Officers, certain information about option exercises and restricted stock vested during fiscal 2014.
Options Exercised and Stock Vested Table
for Fiscal 2014
| |
Option Awards | | |
Stock Awards | |
Named Executive Officer | |
Number of Shares Acquired on Exercise | | |
Value Realized on Exercise (a) | | |
Number of Shares Acquired on Vesting | | |
Value Realized on Vesting (a) | |
Mark J. Pykett, V.M.D.,
Ph.D. | |
| — | | |
$ | — | | |
| 100,000 | | |
$ | 202,900 | (b) |
Ricardo J. Gonzalez | |
| — | | |
$ | — | | |
| — | | |
$ | — | |
Frederick O. Cope, Ph.D. | |
| — | | |
$ | — | | |
| — | | |
$ | — | |
Brent L. Larson | |
| 96,433 | | |
$ | 235,100 | | |
| — | | |
$ | — | (c)(d)(e)
|
Cornelia B. Reininger, M.D., Ph.D. | |
| — | | |
$ | — | | |
| — | | |
$ | — | |
Thomas H. Tulip, Ph.D. | |
| — | | |
$ | — | | |
| 13,418 | | |
$ | 26,780 | (f) |
| (a) | Computed using the fair market value of the stock on the date prior to or the date of exercise or vesting, as appropriate,
in accordance with our normal practice. |
| (b) | On March 17, 2014, 100,000 shares of Dr. Pykett’s restricted stock vested in accordance with the terms of his restricted
stock agreement. The market price of the stock on the last trading day prior to the vesting date was $2.03 per share. |
| (c) | On January 7, 2014, Mr. Larson exercised options to purchase 70,000 shares of common stock at an exercise price of $0.30 per
share. After canceling 34,308 shares to cover the exercise price and related taxes, we issued 35,692 shares of common stock to
Mr. Larson. The market price of the stock on the last trading day prior to the vesting date was $1.93 per share. |
| (d) | On March 10, 2014, Mr. Larson exercised options to purchase 50,000 shares of common stock at an exercise price of $0.49 per
share. After canceling 12,312 shares to cover the related taxes, we issued 37,688 shares of common stock to Mr. Larson. The market
price of the stock on the last trading day prior to the vesting date was $1.99 per share. |
| (e) | On December 10, 2014, Mr. Larson exercised options to purchase 50,000 shares of common stock at an exercise price of $0.39
per share. After canceling 26,947 shares to cover the exercise price and related taxes, we issued 23,053 shares of common stock
to Mr. Larson. The market price of the stock on the last trading day prior to the vesting date was $1.31 per share. |
| (f) | On October 6, 2014, 20,000 shares of Dr. Tulip’s restricted stock vested upon the partnering of Lymphoseek in two countries
in Asia other than Japan. After canceling 6,582 shares to cover the related taxes, we issued 13,418 shares of common stock to Dr.
Tulip. The market price of the stock on the vesting date was $1.34 per share. |
Compensation of Non-Employee Directors
Each non-employee director received an annual
cash retainer of $50,000 during the fiscal year ended December 31, 2014. The Chairman of the Company’s Board of Directors
received an additional annual retainer of $30,000, the Chairman of the Audit Committee received an additional annual retainer of
$10,000, and the Chairman of the CNG Committee received an additional annual retainer of $7,500 for their services in those capacities
during 2014. We also reimbursed non-employee directors for travel expenses for meetings attended during 2014.
Each non-employee
director also received 20,000 shares of restricted stock during 2014 as a part of the Company’s annual stock incentive grants,
in accordance with the provisions of the Navidea Biopharmaceuticals, Inc. Fourth Amended and Restated 2002 Stock Incentive Plan.
The restricted stock granted will vest on the first anniversary of the date of grant. The aggregate number of equity awards outstanding
at February 28, 2015 for each Director is set forth in the footnotes to the beneficial ownership table provided in “Securities
Ownership of Certain Beneficial Owners and Management” above. Directors who are also officers or employees of Navidea do
not receive any compensation for their services as directors.
The following table sets forth certain information
concerning the compensation of non-employee Directors for the fiscal year ended December 31, 2014.
Name | |
(a) Fees Earned or Paid in Cash or Stock | | |
(b),(c) Option Awards | | |
(d),(e) Stock Awards | | |
All Other Compensation | | |
Total Compensation | |
Peter F. Drake, Ph.D. | |
$ | 58,859 | | |
$ | — | | |
$ | 36,600 | | |
$ | — | | |
$ | 95,459 | |
Brendan A. Ford | |
| 61,359 | | |
| — | | |
| 36,600 | | |
| — | | |
| 97,959 | |
Michael M. Goldberg, M.D. | |
| 50,000 | | |
| — | | |
| 36,600 | | |
| — | | |
| 86,600 | |
Perry A. Karsen (f) | |
| 45,755 | | |
| — | | |
| 37,400 | | |
| — | | |
| 83,155 | |
Eric K. Rowinsky, M.D. | |
| 50,000 | | |
| — | | |
| 36,600 | | |
| — | | |
| 86,600 | |
Gordon A. Troup | |
| 85,000 | | |
| — | | |
| 36,600 | | |
| — | | |
| 121,600 | |
| (a) | Amount represents fees earned during the fiscal year ended December 31, 2014 (i.e., the year to which the service relates).
Quarterly retainers and meeting attendance fees are paid during the quarter following the quarter in which they are earned. |
| (b) | Amount represents the aggregate grant date fair value in accordance with FASB ASC Topic 718. Assumptions made in the valuation
of stock option awards are disclosed in Note 1(e) of the Notes to the Consolidated Financial Statements in the Company’s
Form 10-K filed March 16, 2015. |
| (c) | At December 31, 2014, the non-employee directors held an aggregate of 93,764 options to purchase shares of common stock of
the Company. Dr. Rowinsky held 73,764 options and Mr. Troup held 20,000 options. |
| (d) | Amount represents the aggregate grant date fair value in accordance with FASB ASC Topic 718. Assumptions made in the valuation
of restricted stock awards are disclosed in Note 1(e) of the Notes to the Consolidated Financial Statements in the Company’s
Form 10-K filed March 16, 2015. |
| (e) | During the year ended December 31, 2014, the non-employee directors were issued an aggregate of 120,000 shares of restricted
stock which vest as to 100% of the shares on the first anniversary of the date of grant. At December 31, 2014, the non-employee
directors held an aggregate of 188,000 shares of unvested restricted stock. Drs. Drake and Rowinsky and Messrs. Ford and Troup
each held 37,000 shares of unvested restricted stock, and Dr. Goldberg and Mr. Karsen each held 20,000 shares of unvested restricted
stock. |
| (f) | Mr. Karsen was appointed to the board on February 17, 2014. |
CODE OF BUSINESS CONDUCT AND ETHICS
We have adopted a code of business conduct
and ethics that applies to our directors, officers and all employees. The code of business conduct and ethics is posted on our
website at www.navidea.com. The code of business conduct and ethics may be also obtained free of charge by writing to Navidea
Biopharmaceuticals, Inc., Attn: Chief Financial Officer, 5600 Blazer Parkway, Suite 200, Dublin, OH 43017.
CERTAIN RELATIONSHIPS AND RELATED PARTY
TRANSACTIONS
We adhere to our Code of Business Conduct
and Ethics, which states that no director, officer or employee of Navidea should have any personal interest that is incompatible
with the loyalty and responsibility owed to our Company. We do not currently have a written policy regarding related party transactions.
When considering whether to enter into a related party transaction, the Board considers a variety of factors including, but not
limited to, the nature and type of the proposed transaction, the potential value of the proposed transaction, the impact on the
actual or perceived independence of the related party and the potential value to the Company of entering into such a transaction.
All proposed transactions with a potential value of greater than $120,000 are approved by the Board.
Effective November 13, 2013, the Company
appointed Michael M. Goldberg, M.D., to serve on its Board of Directors. At the time of his appointment, Dr. Goldberg was Portfolio
Manager of Platinum-Montaur Life Sciences, LLC, a Delaware limited liability company (Platinum).
Dr. Goldberg accepted his appointment to
serve on the Company’s Board of Directors in accordance with the provisions of a Director Agreement, dated November 13, 2013,
between the Company and Dr. Goldberg. Pursuant to the terms of the Director Agreement, Dr. Goldberg has acknowledged and agreed
that, for as long as he is a member of the Board of Directors, he will not, directly or indirectly, have any power to direct or
cause the direction of the voting or disposition of any securities of the Company directly or beneficially owned by Platinum or
its affiliates.
Dr. Goldberg has advised the Company that
he separated his and Montaur’s affiliation with Platinum subject to the completion of final financial terms associated with
the separation, and has no continuing involvement with management of the investment portfolios of Platinum or its affiliates. He
has not advised the Company of the specific terms or timing of such separation.
SEC disclosure rules regarding transactions
with “related persons” of an issuer require the Company to provide information about transactions in which Dr. Goldberg
had a direct or indirect material interest, even though Dr. Goldberg was not a “related person” of the Company at the
time of the transactions described below.
As of March 31, 2015, Platinum beneficially
owned approximately 11,454,831 shares of our common stock, excluding 14,777,130 shares of our common stock issuable upon the conversion
of 4,519 shares of Series B Convertible Preferred Stock.
In July 2012, we entered into a $35 million
credit facility with Platinum (the Platinum Loan Agreement). In March 2014, in connection with entering into a Loan and Security
Agreement (the Oxford Loan Agreement) with Oxford Finance LLC (Oxford), providing for a loan to the Company of $30 million, we
entered into a second amendment to the Platinum Loan Agreement (the Second Platinum Amendment). Concurrent with the execution of
the Second Platinum Amendment, the Company delivered an Amended and Restated Promissory Note (the Second Amended Platinum Note)
to Platinum, which amended and restated the First Amended Platinum Note. The Second Amended Platinum Note adjusted the interest
rate to the greater of (i) the United States prime rate as reported in The Wall Street Journal plus 6.75%, (ii) 10.0%, and (iii)
the highest rate of interest then payable by the Company pursuant to the Oxford Loan Agreement plus 0.125%. Navidea, Platinum,
and Oxford also entered into a Subordination Agreement, providing for subordination of the Company’s indebtedness under the
Platinum Loan Agreement to the Company’s indebtedness under the Oxford Loan Agreement, among other customary terms and conditions.
In May 2015, the Company borrowed from Capital
Royalty Partners II L.P. and affiliated lenders (Lenders) a total of $50,000,000 (the CRG Loan) pursuant to a Term Loan Agreement
(the CRG Loan Agreement), and used a portion of the proceeds to repay all amounts outstanding under the Oxford Loan Agreement in
the amount of $31.6 million, which included payments of $289,000 as a pre-payment fee and $2,385,000 as an end-of-term final payment
fee.
In connection with the Company entering
into the CRG Loan, the Company and Platinum entered into a Third Amendment (the Third Platinum Amendment) to the Platinum Loan
Agreement. Platinum and the Lenders also entered into a Subordination Agreement (the Subordination Agreement) providing for the
subordination of the Company’s indebtedness to Platinum under the Platinum Loan Agreement to the Company’s indebtedness
under the CRG Loan Agreement, among other customary terms and conditions. Contemporaneously with the execution of the Third Platinum
Amendment, the Company delivered a Third Amended and Restated Promissory Note (the Third Amended Platinum Note), which amends and
restates the Second Amended Platinum Note. Among other things, the Third Platinum Amendment (i) extends the term of the Platinum
Loan Agreement until a date six months following the maturity date or earlier repayment of the CRG Loan, and (ii) changes the provisions
of the Platinum Loan Agreement governing Platinum’s right to convert advances into common stock of the Company. The Platinum
Loan Agreement formerly provided for the optional conversion of advances made on or after June 25, 2013 beginning two (2) years
from the date of the advance at conversion price equal to the lesser of (i) 90% of the lowest volume weighted average price for
the 10 trading days preceding the date of such conversion request, or (ii) the average volume weighted average trading price for
the 10 trading days preceding the date of such conversion request. Under the Third Platinum Amendment, the conversion right now
applies to all advances made under the Platinum Loan Agreement, but not until such time as the daily volume weighted average price
of the Company’s common stock for the ten (10) preceding trading days exceeds $2.53 per share.
During 2014, the largest aggregate amount
of principal outstanding under the Platinum credit facility was $3.2 million, and as of May 15, 2015, the amount of principal outstanding
was $7.7 million.
In March 2015, Macrophage Therapeutics,
Inc. (MT) entered into an agreement to sell up to 50 shares of its Series A Convertible Preferred Stock (MT Preferred Stock) and
warrants to purchase up to 1,500 common shares of MT (MT Common Stock) to Platinum and Dr. Michael Goldberg for a purchase price
of $50,000 per unit. A unit consists of one shares of MT Preferred Stock and 30 warrants to purchase MT Common Stock. Under the
agreement, 40% of the MT Preferred Stock and warrants are committed to be purchased by Dr. Goldberg, and the balance by Platinum.
The full 50 shares of MT Preferred Stock and warrants to be sold under the agreement are convertible into, and exercisable for,
MT Common Stock representing an aggregate 1% interest on a fully converted and exercised basis. Navidea owns the remainder of the
MT Common Stock. On March 11, 2015, definitive agreements with the investors were signed for the sale of the first tranche of 10
shares of MT Preferred Stock and warrants to purchase 300 shares of MT Common Stock to these investors, with gross proceeds to
MT of $500,000.
In addition, we entered into an Exchange
Agreement with the investors providing them an option to exchange their MT Preferred Stock for our common stock in the event that
MT has not completed a public offering with gross proceeds to MT of at least $50 million by the second anniversary of the closing
of the initial sale of MT Preferred Stock, at an exchange rate per share obtained by dividing $50,000 by the greater of (i) 80%
of the twenty-day volume weighted average price per share of our common stock on the second anniversary of the initial closing
or (ii) $3.00. To the extent that the investors do not timely exercise their exchange right, MT has the right to redeem their MT
Preferred Stock for a price equal to $58,320 per share. We also granted MT an exclusive license for certain therapeutic applications
of the Manocept technology.
Section
16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange
Act of 1934 requires our officers and directors, and greater than 10% stockholders, to file reports of ownership and changes in
ownership of our securities with the Securities and Exchange Commission. Copies of the reports are required by SEC regulation to
be furnished to us. Based on our review of these reports and written representations from reporting persons, we believe that all
reporting persons complied with all filing requirements during the fiscal year ended December 31, 2014, except for: Frederick O.
Cope, Ph.D., Brent L. Larson, Mark J. Pykett, V.M.D., Ph.D., William J. Regan, Cornelia B. Reininger, M.D., Ph.D., and Thomas H.
Tulip, Ph.D., who each had one late Form 4 filing related to a January 2014 grant of stock options, and William J. Regan, who had
one late Form 4 filing related to a May 2014 purchase of stock on the open market.
FEES OF THE INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
Audit Fees. The aggregate
fees billed and expected to be billed for professional services rendered by BDO USA, LLP, primarily related to the audit of the
Company’s annual consolidated financial statements for the 2014 fiscal year, the audit of the Company’s internal control
over financial reporting as of December 31, 2014, the reviews of the financial statements included in the Company’s Quarterly
Reports on Form 10-Q for the 2014 fiscal year, and consents related to the Company's registration statements during the 2014 fiscal
year, were $249,500 (including direct engagement expenses).
The aggregate fees billed for professional
services rendered by BDO USA, LLP, primarily related to the audit of the Company’s annual consolidated financial statements
for the 2013 fiscal year, the audit of the Company’s internal control over financial reporting as of December 31, 2013, and
the reviews of the financial statements included in the Company’s Quarterly Reports on Form 10-Q for the 2013 fiscal year,
were $227,075 (including direct engagement expenses).
Audit-Related Fees. No fees
were billed by BDO USA, LLP for audit-related services for the 2014 or 2013 fiscal years.
Tax Fees. No fees were billed
by BDO USA, LLP for tax-related services for the 2014 or 2013 fiscal years..
All Other Fees. No fees were
billed by BDO USA, LLP for services other than the audit, audit-related and tax services for the 2014 or 2013 fiscal years.
Pre-Approval Policy. The Audit
Committee is required to pre-approve all auditing services and permitted non-audit services (including the fees and terms thereof)
to be performed for the Company by its independent auditor or other registered public accounting firm, subject to the de minimis
exceptions for permitted non-audit services described in Section 10A(i)(1)(B) of the Securities Exchange Act of 1934 that are approved
by the Audit Committee prior to completion of the audit. The Audit Committee, through the function of the Chairman, has given general
pre-approval for 100% of specified audit, audit-related, tax and other services.
COST OF SOLICITATION OF PROXIES
We will pay the cost of this solicitation.
We may request persons holding shares in their names for others to forward soliciting materials to their principals to obtain authorization
for the execution of proxies, and we will reimburse such persons for their expenses in so doing.
GOVERNANCE MATERIALS AVAILABLE ON OUR
WEBSITE
Stockholders may find the following information
on the Company’s website at www.navidea.com.
| · | Navidea’s Code of Business Conduct and Ethics |
| · | Management and Board of Director biographies |
| · | Information regarding securities transactions by directors and officers |
| · | Standing Committee Charters for Audit Committee and Compensation and Nominating and Governance Committee |
STOCKHOLDER PROPOSALS
A stockholder proposal intended for inclusion
in the proxy statement and form of proxy for the Annual Meeting of Stockholders of the Company to be held in 2016 must be received
by the Company before March 18, 2016, at its executive offices, Attention: Brent Larson. Any stockholder proposal submitted outside
the processes of Rule 14a-8 under the Securities Exchange Act of 1934 for presentation at our 2016 Annual Meeting will be considered
untimely for purposes of Rule 14a-4 and 14a-5 if notice thereof is received by us after April 21, 2016.
A stockholder who wishes to nominate a candidate
for election to the Board of Directors must follow the procedures set forth in Article III, Section 2 of our Bylaws. A copy of
these procedures is available upon request from the Company at 5600 Blazer Parkway, Suite 200, Dublin, OH 43017, Attention: Brent
Larson. In order for a stockholder to nominate a candidate for the Board of Directors election at the 2015 Annual Meeting, notice
of the nomination must be delivered to the Company’s executive offices, Attention: Brent Larson, before February 6, 2016.
OTHER BUSINESS
The Board of Directors does not intend to
present, and has no knowledge that others will present, any other business at the Annual Meeting. If, however, any other matters
are properly brought before the Annual Meeting, it is intended that the persons named in the enclosed proxy will vote the shares
represented thereby in accordance with their best judgment.
WHERE YOU CAN FIND MORE INFORMATION;
INCORPORATION BY REFERENCE
The Company files annual, quarterly and
current reports, proxy statements and other information with the SEC under the Exchange Act. You may read and copy this information
at, or obtain copies of this information by mail from, the SEC’s Public Reference Room, 100 F Street, N.E., Washington, D.C.
20549, at prescribed rates. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room. The
Company’s filings with the SEC are also available to the public from commercial document retrieval services and at the website
maintained by the SEC at www.sec.gov.
No persons have been authorized to give
any information or to make any representations other than those contained in this proxy statement and, if given or made, such information
or representations must not be relied upon as having been authorized by us or any other person. This proxy statement is dated June
5, 2015. You should not assume that the information contained in this proxy statement is accurate as of any date other than that
date, and the mailing of this proxy statement to stockholders shall not create any implication to the contrary.
YOUR VOTE IS IMPORTANT. Whether or not
you plan to attend the Annual Meeting, please complete, sign and date the enclosed proxy card and return it promptly in the envelope
provided or vote through the Internet or by telephone as described in the enclosed proxy card.
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024